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PART I: A CONCISE ASYMMETRIC SYNTHESIS OF MICROTUBULE 
INHIBITOR TRYPROSTATIN B 
Tryprostatin (TPS) A and B, microtubule inhibitor, are the members of a family of prenylated Trp-
Pro diketopiperzine alkaloids. These two natural products were isolated in 1995 from the 
fermentation broth of Aspergillus fumigatus BM939 by Osada and coworkers. TPS and related 
diketopiperazine containing compounds such as phenylahistins, spirotryprostatins, and 
cyclotryprostatins are inhibitors of the mammalian cell cycle. They prevent cell cycle progression 
at the G2/M phase through a unique mechanism consisting of inhibiting the interaction between 
microtubule assisted proteins (MAP-2) and the C-terminal end of tubulin. TPS A and B hold great 
potential because they were found to have inhibitory activity on the cell cycle progression of mouse 
tsFT210 cells with minimum inhibitory concentration (MIC) values of 16.4 μM for TPS A and 4.4 





procedure have limited their development as viable anti-cancer therapeutics. On the other hand, 
their interesting biological activity and simple structure have drawn attention from the synthetic 
community, and several total syntheses have been reported. Herein, a concise and efficient total 
synthesis of tryprostatin B was described. The key step was the preparation of a diprenylated 
gramine salt where the prenyl group was incorporated at the 2-position of the indole moiety by 
direct lithiation of the Boc-protected gramine. We also developed and optimized the asymmetric 
phase-transfer-catalyzed reaction with diprenylated gramine salt to provide the C2-prenyl 
tryptophan intermediate resulting in 93% enantiomeric excess (ee) and 65% yield. The total 
synthesis of tryprostatin B was done in six steps with 35% overall yield.  
 
PART II: SYNTHESIS AND BIOLOGICAL ASSESSMENT OF HISTONE 
DEACETYLASE INHIBITORS 
 
Histone acetylation and deacetylation in eukaryotic cells is delicately maintained by histone 
acetyltransferases (HAT) and histone deacetylases (HDAC). These enzymes are responsible for 
the modifications to chromatin structures and regulation of transcription.  In general HAT activity 
leads to an increase in gene transcription through the opening of the chromatin framework by 
adding acetyl groups. In contrast, HDAC catalyze the removal of the acetyl groups on lysine 
residues located on the NH2 terminal tails of core histones, which leads to gene repression by 
chromatin condensation. As a result, inhibition of HDAC activity can result in a general 
hyperacetylation of histones, which is followed by the transcriptional activation of certain genes 
through relaxation of the DNA conformation.  These posttranslational modifications are essential 





vorinostat (SAHA), romidepsin (FK228) are usually very potent, moderately isoform-selective, 
but are often associated with poor solubility, ineffective against solid tumors and excessive 
cytotoxicity. To overcome these limitations of the market drugs, a group of HDAC inhibitors were 
synthesized based on market drug FK228. One of our synthetic compounds was found to be active 
against class I HDAC and possibly effective against Alzheimer’s disease. Further investigations, 
including microsomal assays and pharmacokinetic studies, are currently underway. 
 
PART III: ACID CATALYZED REACTIONS OF AROMATIC KETONES 
WITH ETHYL DIAZOACETATE 
 
3-Hydroxyacrylates or 3-oxo-esters are useful precursors for synthesizing important biologically 
active and pharmaceutically important compounds due to their multiple functionality and 
preferable substrate scope. These synthons are also applied for the construction of quaternary 
carbon center containing compounds due to the presence of an active prochiral center. In 1998 and 
later in 2004, our group reported the unprecedented reactions of aromatic aldehydes with ethyl 
diazoacetate (EDA) in the presence of the iron Lewis acid and the Brønsted type acid, respectively. 
This novel reaction formed 3-hydroxyacrylates by an unusual 1, 2-aryl shift. In this project, we 
extended this method for less reactive aromatic ketones with EDA using Brønsted acid catalyst to 
produce the 3-hydroxyacrylates. 3-hydroxyacrylates and 3-oxo-esters were isolated from the 
reactions by 1,2-aryl/alkyl shifts. The products from these reactions can be applied to make all-
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PART I: A CONCISE ASYMMETRIC SYNTHESIS OF MICROTUBULE 


















Microtubules are ropelike polymers of tubulin proteins, found in all eukaryotic cells and they are 
key components of the cytoskeleton (Figure 1.1).1 They are formed by the polymerization of a 
dimer of two globular proteins, alpha (α)- and beta (β)-tubulin into protofilaments that can then 
associate laterally to form a hollow tube, the microtubule.2 The most common form of a 
microtubule consists of 13 parallel rows and can grow as long as 50 micrometers in the tubular 
arrangement.3,4 The outer diameter of microtubule is about 24 nm and the inner diameter is about 
12 nm.4,5  Microtubules are long, hollow cylinders made up of polymerized α- and β-tubulin dimers 
in eukaryotes cells. These two tubulin proteins join back to back and make polymers.6 
Microtubules have a distinct polarity that is critical for their biological function. When α-tubulin 
exposed it is called negative end and when β-tubulin exposed it is called positive end. While 
microtubule elongation can occur at both the positive end and negative ends, it is significantly 
more rapid at the positive end.7 Microtubule inhibitor binds to β-tubulin to stop polymerization. 
Microtubules are important for the function of cellular processes. They are involved in maintaining 
the shape and size of the cell, and transport materials in the cell.8 Microtubules are also involved 
in cell division system by mitosis and meiosis and are the major constituents of mitotic spindles, 
which are used to pull eukaryotic chromosomes apart.9 
 
 





1.1.2. Microtubules in Cell Division 
 
The cell cycle is the vital process where a single cell divides into two different cells. It is the series 
of events by which a cell duplicates its DNA (DNA replication) and divides of cytoplasm and 
organelles to produce two daughter cells.10 After formation of daughter cells, each of the daughter 
cell begin the process of new cell cycle.11 Actually, the cell cycle is broken down into four phases 
(Figure 1.2). In Gap 1 phase, also known as G1 phase, cells increase in size and make sure 
everything is ready for DNA replication and go to the synthesis (S) phase. In the S-phase where 
DNA replication occurs.  In the Gap 2 phase, also known as G2 phase, the cells increase in size 
and ensures that cell is ready to enter the Mitosis (M) phase. In the Mitosis (M) phase, cells growth 









1.1.3. How Microtubule Inhibitors Work 
In the cell cycle process, cells are entered the four different phases; G1 phase, S-phase, G2-phase, 
and M-phase. There are two different check points in the cell cycle, G1/S check point and G2/M 
check point (Figure 1.3). In the mitosis (M) phase, there are four different sub-phases; prophase, 
metaphase, anaphase, and telophase (Figure 1.4).11-13 The earliest sub-phase in mitosis phase is 
prophase, in this phase early stage spindle formation occurs. The condensation of the chromatin 
and the disappearance of the nucleolus are the two main function in prophase.13 Anti-cancer drugs 
are designed based on these two check points, some drugs control the G1/S check point and stop 
DNA replication, and other drugs control the G2/M check point and stop cell division. Microtubule 
inhibitors bind with beta-tubulin at the G2/M check point and stop the early-stage spindle 
formation at metaphase stage.14 
 





Mitotic spindles sometimes called the spindle apparatus is used by nearly all eukaryotic cells to 
separate their chromosomes during cell division. This includes the microtubule-associated proteins 
(MAPs) and the microtubule organization center (MTOC).15 Cytoskeletal drugs are small 
molecules that interact with action or tubulin.  Some drugs destabilize the microtubules, and others 
prevent polymerization. Microtubule inhibitors such as tryprostatins bind to actin monomers and 
prevents polymerization of actin filaments and stop pomerization.16 Microtubule inhibitors have 
been also able to bind to tubulin protein and change its activation site, for this reason the 
microtubule dynamics are manipulated. By the interference of spindle formation, microtubule 
inhibitor can prevent a cell from going into a cell cycle and can lead to programmed cell death or 
apoptosis.17 Microtubule dynamics can be suppressed by both microtubule stabilizer and 
destabilizers. The taxane family, for example, paclitaxel act as stabilizer anti-cancer drug that 
stabilize the microtubule, preventing it from disassembling, and on the other hands, vinca 
alkaloids, for example, vinblastine-vincristine have the opposite effect, and these destabilize the 











1.1.4. Microtubule Inhibitors  
Microtubule inhibitors such as vinca alkaloids (vinblastine, vincristine), taxanes (paclitaxel), and 
indole based diketopiperazine (tryprostatins) compounds destabilize microtubules and suppress 
microtubule dynamics proper mitotic function, effectively blocking cell cycle progression and 
resulting in apoptosis (Figure 1.5).19,20 To elucidate the biological function of a cellular factor, 
development of specific inhibitors is a successful approach. There are many examples applying 
inhibitors to elucidate the regulatory mechanism of the cell cycle. Specific and effective inhibitors 
of the cell cycle should be useful tools for the investigation of the cell cycle mechanism and good 
candidates for cancer chemotherapy.21 
 






1.2. Isolation and Background of Tryprostatin A and B  
 
Tryprostatin (TPS) A and B (Figure 1.6) are members of a family of prenylated Trp-Pro 
diketopiperzine alkaloids. These two natural products were isolated in 1995 from the fermentation 
broth of Aspergillus fumigatus BM939 by Osada and coworkers.22 These two compounds operate 
through a mode of action by inhibiting multiple-drug resistance, which is a major obstacle in 
chemotherapy, showing promise as anti-cancer anti-mitotic agents. TPS and related 
diketopiperazine ring containing compounds such as phenylahistins, spirotryprostatins, and 
cyclotryprostatins are inhibitors of the mammalian cell cycle.23-25 It was found that tryprostatins A 
1 and B 2 completely inhibited cell cycle progression of tsFT210n cells in the G/2M phase at a 
final concentration of 50 µg/ml of 1 and 12.5 µg/ml of 2, respectively.25 They prevent cell cycle 
progression at the G2/M phase through a unique mechanism consisting of inhibiting the interaction 
between microtubule-assisted proteins (MAP-2) and the C-terminal end of tubulin. TPS A and B 
have great potential because they were found to have inhibitory activity on the cell cycle 
progression of mouse tsFT210 cells with minimum inhibitory concentration (MIC) values: 16.4 
μM for TPS A and 4.4 μM for TPS B, respectively.23,26 Multidrug resistance (MDR) in human 
cancers is one of the major causes of failure in chemotherapy. Fungal secondary metabolite 
Tryprostatin A (TPS-A) was analyzed with regard to its potency to reverse the Breast Cancer 
Resistance Protein (BCRP) mediated drug resistance. No cytotoxicity was seen at effective 
concentrations, indicating that TPS-A is a novel BCRP inhibitor. The scarcity of TPS A and B in 
nature and long, low-yielding synthetic procedures have limited their development as viable 






TPS A and B contain a 2-prenylindole moiety and diketopiperazine unit.34 
 
Figure 1.6: Structure of Microtubule Inhibitor, Tryprostatin A and B 
 
Like TPS A and B, there are a lot of natural products are reported which contain 2-prenylindole 
moiety and diketopiperazine units such as spirotryprostatin A and B (Figure 1.7). These two are 
isolated from Aspergillus fumigatus is a species of fungus of sea sediment. Like several other 
indolic alkaloids, they have been found to have anti-mitotic properties, and as such they have 
become of great interest as anti-cancer drugs. 
 






Osada et al. isolated TPS A and B, spirotryprostatin A and B, and new compounds called the 
cyclotryprostatins A-D which belong to the family of Fumitregorins.35 Cyclotryprostatins A-D also 
prevent cell cycle progression at the G2/M phase. They inhibited cell cycle progression of tsFT210 
cells in the G2/M phase with IC50 values of 5.6µM, 19.5µM, 23.4µM, and 25.3µM, respectively 
(Figure 1.8).36-37 Fumitremorgins A-C, that belong to a class of naturally diketopiperazines, are 









Tryprostatins are important compounds for treating cancer, via microtubule inhibition.  
Microtubules are promising targets for stopping the cell division of cancer cells.39,40 The 
interesting biological activity of these alkaloids has stimulated interest in their total synthesis.  The 
scarcity of TPS A and B in nature and long, low-yielding synthetic procedures have limited their 
development as viable anticancer therapeutics. On the other hand, their interesting biological 
activity and simple structure have drawn attention from the synthetic community, and several total 
syntheses have been reported.41-52 The first total synthesis of the Tryprostatin B was reported by 
Danishefsky et al. via the chloroindolenine/borane approach. Illustrated by the scheme below.41  
 
1.2.1. Danishefsky’s Synthesis of Tryprostatin B in 1996 
In the Danishefsky’s synthesis of tryprostatin B in 1996, the N-phthaloyl-L-tryptophan methyl 
ester was treated with tert-butyl hypochlorite to generate the chloroindolenine intermediate at 0 
°C. This intermediate was then treated with tri-n-butylprenyl stannane and followed by rapid 
addition of boron trichloride (two equivalents) to provide the desired 2-prenyl tryptophan 
derivative.  This is the way to introduce a prenyl function at the 2-position of a 3-substituted indole. 
Removal of the N-phthaloyl protecting group generated the required L-2-prenyltryptophan methyl 
ester.  The coupling reaction between the 2-prenyl tryptophan and the N-Boc-L-proline acid 
fluoride to afford dipeptide.  The Boc-protecting group was removed on treatment of material with 
trimethylsilyl iodide in acetonitrile to afford the free amine. When the free amine was stirred in a 
solution of ammonia/methanol for 24 h, the formation of the diketopiperazine unit resulted in 





















































































1.2.2. Synthesis of Tryprostatin A by Cook et al. in 1997 
 
The first total synthesis of tryprostatin A was completed by Cook and his coworkers via a 
regiospecific bromination process coupled with the Schöllkopf chiral auxiliary.42-44 The 
regiospecific bromination of 3-methylindoles were achieved at the indole 2-position via an 
electrophilic process or at the 3-methyl position under free radical conditions, this method 





The synthesis began with the Fischer indole cyclization via a Japp-Klingmann azo-ester 
intermediate (Scheme 1.2). The azo-ester intermediate was formed when m-anisidine was treated 
with sodium nitrite and concentrated aqueous HCl at 0 °C, followed by the addition of ethyl α-
ethylacetoacetate, this intermediate was heated in a solution of 3 N ethanolic HCl, the desired ethyl 
6-methoxy-3-methylindole- 2-carboxylate was obtained. Alkaline hydrolysis of the ester under 
yielded the corresponding carboxylic acid which was converted into 6-methoxy-3-methyl indole 
in excellent yield via the subsequent copper/quinoline-mediated decarboxylation sequence. To 
protect indole N(H) moiety, 6-methoxyindole was treated with di-tert-butyl decarbonate in 
presence dimethoxyamonopyridine. The protected 3-methylindole was then reacted with N-
bromosuccinamide (NBS) in carbon tetrachloride to provide the 2-bromoindole as illustrated in 
Scheme 2. When 2-bromoindole was reacted with NBS under free radical conditions, 
azobisisobutyronitrile (AIBN), dibromide indole was obtained in 93% yield. Dibromide was 
coupled with the Schöllkopf chiral auxiliary at -78 °C, a pyrazine compound was obtained in 91% 
yield. The pyrazine was treated with n-butyllithium at -78 °C, followed by addition of prenyl 
bromide, 2-isoprenylpyrazine was isolated in 86% yield. The pyrazine group was removed under 
acidic conditions (aqueous HCl, THF) in 94% yield to provide D-valine ethyl ester and the 2-
prenyltryptophan. The 6-methoxy-2-prenyltryptophan was stirred with N-(trichloroethoxy 
carbonyl)(Troc)-L-prolyl chloride in the presence of triethylamine in CH2Cl2 at 0 °C, the desired 
dipeptide was obtained. The Troc protecting group was removed by heating with Zn (dust) in 
refluxing MeOH. Finally, formation of the diketopiperazine unit and removal of Boc-protecting 
group from the indole N(H) function were achieved when dipeptide was heated at 160 °C (neat) 







Scheme 1.2. Cook’s Synthesis of Tryprostatin A 
Later the synthesis of tryprostatin A and B as well as their enantiomers was developed by Cook 
(Scheme 1.3).44 In order to introduce the prenyl group at the indole C-2 position of and decrease 
the number of steps earlier reported by Cook et al. LDA was employed to form the anion at C(2).  
The indole was stirred with LDA at -78 ˚C followed by the addition of dry, pure prenyl bromide 
to furnish 2-prenylpyrazine. This was an improvement over the synthesis of 2-prenylpyrazine, and 
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Tryptophan preparation for the synthesis of tryprostatin A and B
Tryptophan preparation for the synthesis of 9-epimer tryprostatin A and B
 
Scheme 1.3. Synthesis Enantiomers of Tryptophans by Cook et al. 
With the key 2-prenyltryptophan derivatives in hand, the diketopiperazine unit was built on as 
illustrated, 2-prenyl-tryptophans were stirred with N-Fmoc-L-prolyl chloride in the presence of 
triethylamine in chloroform at room temperature.  The Fmoc-protecting group was removed by 
addition of diethylamine (DEA) in acetonitrile. Formation of the diketopiperazine as well as the 
removal of the Boc-protecting group from the indole N(H) were achieved by heating in refluxing 
xylenes in high dilution.  A stereospecific, enantiospecific total synthesis of tryprostatin A and B 
was accomplished via alkylation of the corresponding 2-lithioindole derivatives.  This procedure 
was also applied to the enantiomers of tryprostatin A and tryprostatin B (Scheme 1.4). The optical 
rotations of the natural products and the enantiomers agreed with those reported by Osada et al. 
for the natural products. This route was used for the total synthesis of the mismatched pairs of 
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R = OMe, ds2-try A
R =H, ds2-try B  





1.2.3. Fukuyama’s Most Recent Synthesis of Tryprostatin A and B in 2010 
Fukuyama and his coworkers synthesized TPS A and B from the Garner aldehyde.51,52 The Garner 
aldehyde was treated with carbon tetrabromide, triphenyl phosphine in presence of triethyl amine 
followed by Grignard reagent ethyl magnesium bromide at 0 °C formed alkyne which was went 
to the Sonogashira coupling with 2-iodoformanilide, partial reduction of the triple bond was 
examined by the treatment with Zn/LiCuBr2 in ethanol gave the desired product along with the 
corresponding amine in 2,2,2-trifluoroethanol as the solvent to suppress the undesired solvolysis 
with 99% yield. Subsequent dehydration with bis(trichloromethyl) carbonate (triphosgene) gave 
the ortho-alkenyl isocyanide and thus set the stage for a radical-mediated cyclization where 2,2’-
azobis(4- methoxy-2,4-dimethylvaleronitrile) (V-70, 20) acts as a radical initiator with a lower 
decomposition temperature. Thus, we established reliable conditions for imidoyl-radical-mediated 
indole synthesis. When this method was applied to the radical cyclization of the isocyanide, 
complete selectivity was observed for the cyclization of the imidoyl radical to give the 2-
stannylindole and by Stille-type coupling reaction. The desired 2-prenyl indole product was 
obtained in only 82% yield with prenyl acetate as the coupling partner in presence of 
triphenylarsine, lithium chloride, and [Pd2(dba)3] as the catalyst. The 2-prenyl indole moiety N(H) 
was protected with a Boc group, hydrolysis of the acetonide, and oxidation of the resulting alcohol 
to the carboxylic acid with 2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPO). Under reflux in N-
methylpyrrolidinone (NMP) conditions, spontaneous cyclization occurred to give tryprostatin B 
(2) in 89% yield. Thus, tryprostatin B was synthesized by Fukuyama and coworkers in 11 steps 
from Garner aldehyde in 33% overall yield on a half-gram scale. By following the similar method, 











1.3. Background of Our Synthesis of Tryprostatin B 
1.3.1. Synthesis of Tryptophan from Acrylate via Gramine 
In 1998, Professor Hossain group discovered an unprecedented reaction for the formation of 3-
hydroxyacrylate from commercially available aldehydes and ethyl diazoacetate (EDA) in presence 
of iron Lewis acid catalyst by a unique 1,2-aryl shift (Scheme 1.6).53 Later, in 2004, same group 
explored catalyst scopes of the reactions with Brønsted type acids, specifically HBF4∙OEt2, for the 
formation of 3-hydroxyacrylates from the corresponding aldehydes and EDA (Scheme 1.6).54 
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Scheme 1.6. Synthesis of Acrylates by Hossain et al. 
3-Hydroxyacrylates are very important synthon for synthesizing important biologically active and 
pharmaceutically important compounds due to the multiple functionality.55,56 Hossain group 
reported a lot of synthesis of biological active compounds including active building blocks such 
as benzofuran, indole, gramine and so on from the 3-hydroxyacylates.57,58 Synthesis of gramine 







Scheme 1.7. Synthesis of Gramine from Acrylates 
After synthesis of several substituted gramine, our group wondered if it would be possible to make 
enatiopure-pure tryptophan using a chiral phase transfer catalyst (PTC). Our group thought that 
this would be interesting chemistry and would be likely to find industrial use of this method as 
tryptophans are important building blocks novel indole-based class of compounds.59 Then, the 
Hossain group developed the following reaction to make tryptophan (Scheme 1.8).60 
 





Hossain and coworkers synthesized several substituted chiral tryptophan from substituted gramine 
in their laboratory.60 Here are some examples in Figure 1.9. 
 
Figure 1.9: Examples of Some Protected Chiral Tryptophans 
When we had chiral tryptophans in our hand, we designed a retrosynthetic scheme for the synthesis 
of tryprostatin B from gramine. The retrosynthetic scheme is illustrated below (Scheme 1.9): 
 





1.3.2. Phase-Transfer-Catalysis (PTC): General Concepts and Mechanism 
In order to endorse the successful alkylation of C2-prenylated protected tryptophan, a basic 
understanding of the phase transfer catalyzed (PTC) reaction is required. In 1971, Starks 
introduced the term phase transfer catalysis where he described a little organic quaternary salt 
dramatically increase the rate of reaction (Scheme 1.10). Reaction between an organic solution of 
an alkyl halide and an inorganic solution of sodium cyanide in presence of tetralkylammonium or 
tetralkylphosphonium salt produced product faster.63 
 
Scheme 1.10. Phase-Transfer-Catalyzed Reactions Reported by Starks 
Cyanide ion is insoluble in organic solvent, so the reaction was unable to continue without the 
presence of phase transfer catalyst (PTC).  PTC carry the nucleophilic cyanide ion from aqueous 
phase to organic phase and exchange the ion with phase transfer catalyst at the interface. The new 
ion pair then travel to the organic phase and reacts with nucleophile (Figure 1.10). 
QCN QBrBr (organic phase)CN
QCN QBr
(aqueous phase)QCNNaBr NaCN QBr  






1.3.3. Prenylation at the C2-Position of Indole Ring in Other Groups 
Tryprostatin (TPS) A and B contain a 2-prenylindole moiety and diketopiperazine unit. The 
prenylation at the C2 position of the indole ring is a big challenge for synthetic chemists; several 
steps have been described in several procedures to introduce the prenyl groups. In these schemes, 
prenylation of C2 position at indole ring are discussed by Danishefsky, Cook, and Fukuyama 
respectively (Scheme 1.11).41, 42, 51 
  






1.3.4. Prenylation at the C2-Position of Indole Ring in Other Groups 
In order to prepare the intermediate prenyl tryptophan, our strategy envisaged the installation of 
the prenyl group at the C2 position of the indole ring of chiral tryptophan 61 Consequently, 
tryptophan was Boc-protected and treated with prenyl bromide in the presence of n-butyllithium 
or lithium diisopropylamide (LDA), the attempts of prenylation were unsuccessful (Scheme 1.12). 
 
Scheme 1.12: Attempt to Synthesize of C2-Prenyl Tryptophan from Tryptophan 
Receiving important data from the reactions, we decided that the prenyl group containing the 
indole moiety of the target compound could be constructed before the PTC reaction. To incorporate 
the prenyl group at the C2 position, we first reacted the Boc-protected gramine with one equivalent 
of prenyl bromide in the presence of n-butyllithium, and the reaction provided exclusively N-






Scheme 1.13: Attempt to Synthesize of C2-Prenyl Tryptophan from Gramine 
 
Scheme 1.14: Synthesis of N-Prenylated Tryptophan 
N-Prenylated gramine salt was found to undergo a PTC reaction with Schiff base in the presence 
of 50% KOH to provide the tryptophan 3 (Scheme 1.15). The formation of compound 4 revealed 
that the N-prenylated gramine salt is also viable for a PTC reaction, and later, it gave a comparable 
yield (75%) to the previously reported reaction involving N-trifluoromethoxybenzyl gramine salt. 
 





To our surprise, we observed during our investigation that using two equivalents of n-butyllithium 
and excess of prenyl bromide (4.5 equiv) led to the formation of the C2, N-diprenylated gramine 
salt in 92% yield. These findings open a new window to synthesize C2 prenylated indole moiety 
in only two steps from gramine. To the best of our knowledge, this is the easiest way to incorpo-
rate the prenyl group at the C2 position of the indole moiety (Scheme 1.16).  
 
Scheme 1.16: Formation of C2, N-Diprenylated Gramine Salt 
To see if the C2 alkylation of indole ring also feasible for other alkyl groups, we reacted Boc-
protected gramine with benzyl bromide. This finding concluded that to synthesize C2 alkylated 
indole moiety in only two steps from gramine, any suitable electrophile could be used for further 
syntheses. The reaction was done with 73% yield (Scheme 1.17).  
 







The structure of C2, N-diprenylated salt was confirmed by X-ray diffractrometry (Figure 1.11).62 
Blocks grown using slow diffusion method: Ethyl Acetate/Hexane 
Analyzed by X-ray diffraction at UCSD with Arnold L. Rheingold 
Unit Cell Dimensions:  a=8.5784(2) Å; b=12.9668(3) Å; c=13.5267(3) Å 
                                      α=109.266(2)°; β=103.084(2)°; γ=107.596(2)° 
Triclinic lattice, P1 space group, Z = 2 molecules per unit cell. R1 = 4.39% 
 





With the C2 prenyl group containing diprenylated gramine salt, we planned to investigate the PTC 
reaction with Schiff base. By performing a racemic PTC reaction of diprenylated, the desired C2-
prenyl tryptophan was isolated in 82% yield (Scheme 1.18). 
 
Scheme 1.18: Racemic PTC Reaction of C2, N-Diprenylated Gramine Salt 
By using a PTC reaction process, it can be easily achieved faster reactions which make fewer 
byproducts and eliminate the need for expensive or dangerous solvents and expensive raw 
materials. This process needs two solvents to dissolve all the reactants in organic phase and catalyst 
and base in aqueous phase. The mechanism of PTC reaction is shown below in Figure 1.12: 
 





1.3.5. Optimization of Phase-Transfer-Catalyzed (PTC) Reaction 
Encouraged by the results from a racemic PTC reaction, we then turned our attention to the 
asymmetric PTC reaction of the diprenylated gramine salt to prepare chiral C2-prenyl tryptophan. 
We did several reactions with different phase transfer catalysts, and we chose Chinchona catalysts 
as well as recently developed Maruoka catalyst (Figure 1.13) as the PTC.60 All the time same 
amounts of reactants, catalyst, base, and solvent were taken. Reactions were run for the same 
reaction time for all the reaction (Scheme 1.19).  
 
Scheme 1.19: Chiral PTC Reaction of C2, N-Diprenylated Gramine Salt 
 
To optimize the reaction conditions for higher asymmetric induction, we investigated the effects 
of catalysts as well as systematic variations in the solvents, mixed solvent systems, temperature, 
and time on enantiodiscrimination. In order to find the best catalyst for high enantiomeric excess 
(ee), several catalysts were screened as presented in Table 1.1. Chiral stationary HPLC showed 
that O-allyl-N-(9-anthracenylmethyl) cinchonidinium bromide (A), which was an effective 







Table 1.1: Optimization of PTC Reaction by Catalyst Screening 
Catalyst Loading 
Rxn # Catalyst % Conversion % ee 
1 A 100 61 
2 B 100 39 
3 C 100 39 
4 D 100 Rac 
5 E 100 ND 
    
We performed several reactions with different phase transfer catalysts, and we chose Chinchona 
catalysts as well as recently developed Maruoka catalyst as the PTC (Figure 1.13). 
 






In order to find the best solvent for high enantiomeric excess (ee), several solvents were examined 
as presented in Table 1.2. Chiral stationary HPLC showed that polar solvents such as 
dichloromethane (56% ee), 1,4-dioxane (61% ee), dimethoxyethane (60% ee), and 1,2-
dicholoroethane (50%) worked well at room temperature (Table 1.2, entries 1-3, 10, and 15). 
Table 1.2: Optimization of PTC Reaction by Solvent Screening 
Solvent Screening  
Rxn # Solvent  Equiv. cat. % Conversion % ee 
1 DCM 0.2 100 56 
2 1,4-Dioxane 0.2 100 61 
3 THF 0.2 95 52 
4 Toluene 0.2 90 38 
5 EtOAc  0.2 80 30 
6 Xylene 0.2 75 18 
7 Chloroform 0.2 NR N/A 
8 ACN 0.2 100 5 
9 Ether 0.2 80 5 
10 DME 0.2 100 60 
11 DMF 0.2 85 Rac 
12 Methylcyclohexane 0.2 80 Rac 
13 Hexane 0.2 75 Rac 
14 Mesitylene 0.2 80 Rac 






Less polar solvents like toluene did not have a satisfactory result due to poor solubility of the Boc 
protected diprenylated gramine salt. To improve the asymmetric induction, we investigated mixed 
solvent systems in different ratios, but no significant improvement was observed at room 
temperature. However, lowering the temperature from 25 °C to 0 °C resulted in an increase of 
enantioselectivity (Table 1, entries 5 and 8). Better enantiomeric excess (88% ee) was obtained in 
a dioxane-chloroform mixture (10:1 ratio) at 0 °C (Table 1.3, entry 8).  
Table 1.3: Optimization of PTC Reaction by Mixture of Solvent Screening 
Solvent Screening  
Rxn # Solvents  Time (hrs) Temp. (°C) % Conversion % ee 
1 
Dioxane:Chloroform  
(1:1) 18 rt 35 73 
2 
Dioxane:Chloroform  
(2:1) 18 -10 65 84 
3 
Dioxane:Chloroform  
(4:1) 18 rt 72 71 
4 
Dioxane:Chloroform  
(5:1) 36 0 70 85 
5 
Dioxane:Chloroform 
(10:1) 18 rt 63 62 
6 
Dioxane:Chloroform 
(10:1) 36 10 100 78 
7 
Dioxane:Chloroform 
(10:1) 18 0 62 87 
8 
Dioxane:Chloroform 
(10:1) 36 0 100 88 
9 
Dioxane:Chloroform 
(10:1) 36 -10 NR NA 
10 
Dioxane:Chloroform 






We were not able to carry out lower temperature reactions with this mixture because of the 
relatively high freezing point of dioxane. Other mixed solvent systems at lower temperature did 
not provide promising results compared to the single solvent system at the same temperature. Then 
we turn our attention to use single solvent at lower temperature. 1, 4-Dioxane, dimethoxyethane, 
dichlomethane, and tetrahydrofuran were selected for lower temperature. By further cooling to -
20 °C, dichloromethane improved the enantioselection up to 93% (Table 1.4, entry 9). During our 
study, it was revealed that a longer reaction length gave a higher conversion to product. 
Table 1.4: Optimization of PTC Reaction by Temperature Screening 
Temperature Screening  
Rxn # Solvent Time (hrs) Temperature (
0
C) % Conversion %ee 
1 1,4-Dioxane 18 10 100 81 
2 1,4-Dioxane 18 0 NR NA 
3 DME 18 10 100 66 
4 DME 18 0 95 72 
5 DME 18 -10 78 71 
6 DME 36 -20 80 85 
7 DCM 18 0 96 60 
8 DCM 18 -10 90 80 
9 DCM 36 -20 85 93 
10 THF 18 0 92 65 
11 THF 18 -10 95 70 







With the optimized reaction conditions (DCM, -20 °C, 72 hrs, 93% ee, and 65 % isolated yield) in 
hand, we then focused on the total synthesis of tryprostatin B from protected chiral protected 
tryptophan. The diphenylmethylene group was removed from protected tryptophan under acidic 
conditions (aqueous HCl, THF) in 97% yield to provide the 2-prenyl tryptophan tert-butyl ester 
10 (Scheme 1.20).64 
 
Scheme 1.20: Deprotection of C2-Prenylated Protected Tryptophan 
Reaction of 10 with the N-Fmoc-L-prolyl chloride in the presence of trimethylamine yielded Fmoc-
protected dipeptide 11 (Scheme 1.21).42 
  
 







The Fmoc protecting group was deprotected with piperidine in dimethylformamide (DMF) 
provided dipeptide in 76% yield (Scheme 1.22).42 
 
Scheme 1.22: Deprotection of Fmoc-Group from Amide Compound 
 
1.3.6. Cyclization of Amide Compound 
Lastly, to synthesize TPS B, we performed the cyclization reaction for the formation of bicyclic 
diketopiperazine unit in dipeptide 12. At the outset of the program, we undertook a study to identify 
an efficient method for cyclization. Initially, to prepare tryprostatin B, we refluxed compound 12 
in xylene/neat heat following a procedure described by Cook et al (Scheme 1.23).42-44 
 





We refluxed compound 12 in N-methyl-2-pyrrolidone (NMP) by following a procedure described 
by Fukuyama et al (Scheme 1.24).51,52 
 
Scheme 1.24: Attempt to Cyclize for Making Diketopiperazine by NMP Reflux 
Their ethyl ester substrate was easily cyclized in reflux condition, whereas our tert-butyl ester 
substrate was difficult to cyclize. We applied an alternative procedure reported by Carvalho and 
coworkers by reacting dipeptide with 20% piperidine in DMF followed by the addition of DIPEA 
in CH3CN at room temperature (Scheme 1.25). However, no desired product resulted from this 
reaction.65 
 
Scheme 1.25: Attempt to Cyclize for Making Diketopiperazine by Piperidine 
Later, cyclization as described by Williams using 2-hydroxypyridine in toluene under reflux was 






Scheme 1.26: Attempt to Cyclize for Making Diketopiperazine by 2-Hydroxypyridine Reflux 
Later, cyclization as described by Danishefsky using ammonia in methanol under reflux was also 
unsuccessful with dipeptide compound 12 (Scheme 1.27).51,52 
 
Scheme 1.27: Attempt to Cyclize for Making Diketopiperazine by Ammonia/Methanol Reflux 
1.3.7. Microwave Reaction 
In seeking a workable solution to the goal of cyclization involving a tert-butyl ester group, we 
applied the microwave method which was developed by Rios et al..67 First, we developed a model 
microwave experiment with a tert-butyl ester group containing compound 14 (Scheme 1.28).  
 





Compound 13 was synthesized from Fmoc-proline and glycine tert-butyl ester through a coupling 
reaction. The model compound was heated in water for 10 min at 250 ̊C and 150 psi using a CEM 
Discover microwave at 250 W. The desired bicyclo[4.3.0]-2,5-diketopiperazine 15 was obtained 
in high yield and NMR was matched with the reported values in the literature (Scheme 1.29).68 
 
Scheme 1.29: Model Microwave Reaction for Diketopiperazine  
 
Encouraged by this successful reaction involving the tert-butyl ester group, we turned our interest 
to the dipeptide 12. Under the above-mentioned microwave conditions, spontaneous cyclization 
occurred to give tryprostatin B in 81% yield.69 The proton and carbon NMR spectra of the final 
com-pound matched with the published data (Scheme 1.30).51 
 
Scheme 1.30: Synthesis of Tryprostatin B by Microwave Reaction 
From our developed method, TPS B was synthesized from the commercially available gramine in 






1.4. Total Synthesis of Tryprostatin B69 
 
Scheme 1.31: Total Synthesis of Tryprostatin B 
 
By following our developed method, we tried to synthesize the total synthesis of TPS A. We 






1.5. Partial Synthesis of Tryprostatin A 
 
Scheme 1.32: Partial Synthesis of Tryprostatin A 
 
By following our developed method, we tried to synthesize the total synthesis of TPS A. These 






In summary, Tryprostatin (TPS) A and B have great potential because they were found to have 
inhibitory activity on the cell cycle progression of mouse tsFT210 cells. Their interesting 
biological activity and simple structure have drawn attention from the synthetic community, and 
several total syntheses have been reported. We described a concise and efficient asymmetric 
synthesis of tryprostatin B. The key steps involved first, the preparation of C2 prenyl gramine salt 
by direct lithiation from Boc protected gramine. This is most unique process by which one can 
incorporate any electrophile at the C2 position of gramine. This method opens a new window for 
the indole based synthetic chemists as well as organic chemists. Second, the asymmetric phase 
transfer catalyzed (PTC) reaction of the prenylated gramine salt. By the PTC reaction, our method 
was most effective because it produced less waste with minimum number of chemicals. The PTC 
reaction was optimized by changing the solvent, temperature, and time. From our developed 
method, C2 prenylated indole was synthesized with only on two steps from gramine and TPS B 
was synthesized in six steps with 35% overall yield. By changing the substituent, our group have 
planned to synthesis of analogs of tryprostatins, and after making the analogs (Figure 1.14) our 
group will see the activity of new synthetic compounds against breast cancer.70,71 Further 









1.7. General Methods and Experimental 
1.7.1. General Consideration  
All reactions were performed under a dry nitrogen atmosphere using standard Schlenk techniques 
unless otherwise noted.  All reaction vessels were flame dried under vacuum and filled with 
nitrogen prior to use. Reagents and solvents were purchased from Sigma-Aldrich, Milwaukee. All 
1H and 13C NMR spectra were recorded in CDCl3 (internal standard: 7.26 ppm, 
1H; 77.16 ppm, 
13C) at room temperature with a Burker 300 MHz and 500 MHz spectrometers. The chemical shifts 
(δ) are given in parts per million (ppm) and the coupling constants in Hertz (Hz). The following 
abbreviations are used: s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet. Previously reported 
compounds were identified by 1H NMR. All new compounds were additionally characterized by 
1H NMR, 13C NMR and high-resolution mass spectrometry (HRMS). HRMS were obtained using 
electrospray ionization (ESI) technique. For column chromatography, silica gel (35-70 microns) 
was used. Thin layer chromatography (TLC) was performed on aluminium backed plates pre-
coated (0.25 mm) with Silica Gel 60 F254 with a suitable solvent system and was visualized using 
UV fluorescence and/or iodine chamber. Enantioselectivity was obtained via chiral high-
performance liquid chromatography (HPLC) using a Waters setup including an In-Line Degasser 
AF, 2998 photodiode array (PDA) detector, and 1525 binary HPLC pump equipped with Breeze 
software. This was equipped with a Chiralcel OD (column no. OD00CE-FF071) column eluting 
with iPrOH/hexane with 0.5 mL/min flow rate at ambient temperature. HPLC grade solvents were 
used in all HPLC analyses. HPLC retention times (tR) of enantiomers are quoted in minutes and 
were determined by comparison to racemic materials. Microwave reaction was done at 250 °C, 





1.7.2. Experimental Methods 




A solution of Boc anhydride (Boc2O) (3.0 g, 13.8 mmol), 4-dimethylaminopyridine (DMAP) (0.14 
g, 1.1 mmol), trimethylamine (TEA) (0.122 mL, 0.88 mmol) in THF (50 mL) was maintained at 0 
°C for 30 min. A solution of gramine 1 (2.0 g, 11.5 mmol) in THF (15 mL) was added dropwise 
through the dropping funnel over a period of 30 min at 0 °C. The reaction mixture was stirred at 0 
°C for 1.5 hours under nitrogen atmosphere. After consumption of starting material, as judged by 
TLC analysis, water (20 mL) was added to the reaction mixture. The aqueous layer was extracted 
with ether (3 x 15 mL), washed with brine (1 x 15 mL). The combined organic layer was dried 
over anhydrous Na2SO4. The crude product was purified with column chromatography on silica 
gel (hexane/EtOAc = 7/3) to give product 2 as a light brown solid (3.1 g, 99%). 1H NMR (CDCl3, 
300 MHz):  8.17 (d, J = 9.0 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.55 (s, 1H), 7.36-7.24 (m, 2H), 
3.60 (s, 2H), 2.33 (s, 6H), 1.69 (s, 9H); 13C NMR (CDCl3, 75 MHz): δ 149.8, 135.6, 130.6, 124.6, 
124.4, 122.6, 119.6, 117.8, 115.1, 83.5, 54.5, 45.4, 28.2; HRMS (ESI+): Calculated (m/z) for 
C16H23N2O2 (M+H)










A solution of Boc anhydride (Boc2O) (0.62 g, 2.8 mmol), 4-dimethylaminopyridine (DMAP) 
(0.029 g, 0.24 mmol), trimethylamine (TEA) (0.039 mL, 0.28 mmol) in THF (15 mL) was 
maintained at 0 °C for 30 min. A solution of tryptophan 4 (1.0 g, 2.4 mmol) in THF (25 mL) was 
added dropwise through the dropping funnel over a period of 30 min at 0 °C. The reaction mixture 
was stirred at 0 °C for 1.5 hours under nitrogen atmosphere. After consumption of starting material, 
as judged by TLC analysis, water (15 mL) was added to the reaction mixture. The aqueous layer 
was extracted with ether (3 x 15 mL), washed with brine (1 x 10 mL). The combined organic layer 
was dried over anhydrous Na2SO4. The crude product was purified with column chromatography 
on silica gel (hexane/EtOAc = 25/1) to give Boc-protected product 5 as a white solid (1.19 g, 97%). 
1H NMR (CDCl3, 300 MHz):  8.16 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 6.0 Hz, 2H), 7.40-7.23 (m, 
9H), 7.12 (t, J = 7.5 Hz, 1H), 6.79 (d, J = 6.0 Hz, 2H),  4.32 (dd, J = 9.0, 6.0 Hz, 1H), 3.37 (dd, J 
= 13.5, 4.5 Hz, 1H), 4.32 (dd, J = 13.5, 7.5 Hz, 1H), 1.64 (s, 9H), 1.49 (s, 9H); 13C NMR (CDCl3, 
75 MHz): δ 170.9, 170.5, 149.7, 139.6, 136.2, 135.4, 130.7, 130.2, 128.8, 128.3, 128.2, 127.9, 
127.7, 124.2, 124.1, 122.2, 119.2, 117.0, 115.0, 83.2, 81.2, 66.1, 28.9, 28.2, 28.1; HRMS (ESI+): 
Calculated (m/z) for C33H37N2O4 (M+H)










A solution of 2 (1.5 g, 5.5 mmol) in THF (15 mL) was taken in three necked round bottomed flask 
and nitrogen was bubbled through the solution for 20 min. This mixture was cooled to -78 °C and 
n-butyl lithium (2.2 mL, 2.5 M, 5.5 mmol) was added dropwise to the reaction mixture maintaining 
a temperature -78 °C over a period of 1 h under nitrogen atmosphere. Prenyl bromide (0.63 mL, 
5.5 mmol) was added to the reaction dropwise through the dropping funnel over a period of 30 
min. The reaction mixture was allowed to warm to room temperature and was stirred overnight. 
After consumption of the starting material, as judged by TLC analysis, water (15 mL) was added 
to the reaction mixture and THF was removed under reduced pressure. The mixture was then 
extracted with CH2Cl2 (3 x 15 mL), the combined organic layers were washed with brine solution 
(1 x 10 mL) and dried over anhydrous Na2SO4 and evaporated in vacuo to obtain crude product. 
The residue was purified with flash column chromatography on silica gel (DCM/MeOH = 20/1) 
to afford 6 as off-white solid (2.1 g, 91 %). 1H NMR (CDCl3, 300 MHz):  8.11 (d, J = 9.0 Hz, 
2H), 8.02 (d, J = 6.0 Hz, 1H), 7.94 (s, 1H), 7.29-7.16 (m, 2H), 5.32 (t, J = 7.5 Hz, 1H), 5.22 (s, 
2H), 4.38 (d, J = 9.0 Hz, 2H), 3.15 (s, 6H), 1.81 (s, 3H), 1.76 (s, 3H), 1.59 (s, 9H); 13C NMR 
(CDCl3, 75 MHz): δ 148.9, 148.8, 135.0, 130.5, 129.8, 125.2, 123.8, 120.3, 115.2, 110.9, 107.6, 
85.0, 61.5, 58.6, 48.4, 28.1, 26.4, 19.5; HRMS (ESI+): Calculated (m/z) for C21H31N2O2 [M]
+: 





Tert-butyl 2-((diphenylmethylene)amino)-3-(1H-indol-3-yl)propanoate (4) 
 
A solution of 7 (1g, 2.4 mmol), N-(diphenylmethylene) glycine tert-butyl ester 6 (0.70 g, 2.4 mmol) 
and tetrabutylammonium iodide (0.18 g 0.47 mmol) in dry DCM (20 mL) was maintained at -20 
°C for 30 minutes. 50% aqueous KOH (1.3 g, 24 mmol) was added to the reaction. Then the 
reaction was stirred overnight. After consumption of the starting material, as judged by TLC, water 
was added, and the aqueous layer was extracted with CH2Cl2 (3 x 25 mL). The combined organic 
layers were dried over anhydrous Na2SO4; the solvent was evaporated in vacuo. The residue was 
purified with flash column chromatography on silica gel (hexane/EtOAc = 10/1) to afford 3 as a 
light-yellow oil (0.75 mg, 75%). Compound 4 was confirmed3 by comparing spectra to known 
NMR. 1H NMR (CDCl3, 500 MHz):  7.99 (brs, 1H), 7.64 (d, J = 5.0 Hz, 2H), 7.39 (t, J = 7.5 
Hz, 1H), 7.33-7.27 (m, 5H),  7.18-7.14 (m, 3H), 7.01-6.96 (m, 2H), 6.44 (d, J = 5.0 Hz, 2H), 4.29 
(dd, J = 10.0, 5.0 Hz, 1H), 3.45 (dd, J = 15.0, 5.0 Hz, 1H), 3.27 (dd, J = 15.0, 10.0 Hz, 1H), 1.45 
(s, 9H); 13C NMR (CDCl3, 125 MHz): δ 171.3, 170.1, 139.7, 136.2, 136.0, 130.1, 128.8, 128.1, 










-ylbut-2-en-1-aminium bromide (7) 
 
A solution of 2 (1.5 g, 5.5 mmol) in THF (25 mL) was taken in three necked round bottomed flask 
and nitrogen was bubbled through the solution for 20 min. This mixture was cooled to -78 °C and 
n-butyl lithium (4.4 mL, 2.5 M, 10.9 mmol) was added dropwise to the reaction mixture 
maintaining a temperature -78 °C over a period of 1 h under nitrogen atmosphere. Prenyl bromide 
(2.8 mL, 24.4 mmol) was added to the reaction dropwise through the dropping funnel over a period 
of 30 min. The reaction mixture was allowed to warm to room temperature and was stirred 
overnight. After consumption of the starting material, as judged by TLC analysis, water (20 mL) 
was added to the reaction mixture and THF was removed under reduced pressure. The mixture 
was then extracted with CH2Cl2 (3 x 15 mL), the combined organic layers were washed with brine 
solution (1 x 10 mL) and dried over anhydrous Na2SO4 and evaporated in vacuo to obtain crude 
product. The residue was purified with flash column chromatography on silica gel (DCM/MeOH 
= 20/1) to afford 7 as a brown solid (2.48 g, 92 %). 1H NMR (CDCl3, 300 MHz):  8.08 (d, J = 
9.0 Hz, 2H), 7.32 (dd, J = 9.0 Hz, 6.0 Hz, 2H), 5.38 (t, J = 7.5 Hz, 1H), 5.27 (s, 2H), 5.04 (s, 1H), 
4.56 (d, J = 6.0 Hz, 2H), 3.91 (s, 2H), 3.17 (s, 6H), 1.93 (s, 3H), 1.88 (s, 3H), 1.80 (s, 3H), 1.67 
(s, 12H); 13C NMR (CDCl3, 75 MHz): δ 149.6, 148.7, 144.1, 135.8, 134.1, 129.0, 124.4, 123.6, 
120.3, 119.8, 114.9, 111.2, 106.0, 85.0, 61.8, 58.1, 48.4, 27.9, 26.8, 26.4, 25.4, 19.5, 18.7; HRMS 
(ESI+): Calculated (m/z) for C26H39N2O2 [M]






aminium bromide (8) 
 
A solution of 2 (1.0 g, 3.6 mmol) in THF (20 mL) was taken in three necked round bottomed flask 
and nitrogen was bubbled through the solution for 20 min. This mixture was cooled to -78 °C and 
n-butyl lithium (2.9 mL, 2.5 M, 7.3 mmol) was added dropwise to the reaction mixture maintaining 
a temperature -78 °C over a period of 1 h under nitrogen atmosphere. Benzyl bromide (2.0 mL, 
16.4 mmol) was added to the reaction dropwise through the dropping funnel over a period of 30 
min. The reaction mixture was allowed to warm to room temperature and was stirred overnight. 
After consumption of the starting material, as judged by TLC analysis, water 15 mL) was added 
to the reaction mixture and THF was removed under reduced pressure. The mixture was then 
extracted with CH2Cl2 (3 x 15 mL), the combined organic layers were washed with brine solution 
(1 x 10 mL) and dried over anhydrous Na2SO4 and evaporated in vacuo to obtain crude product. 
The residue was purified with flash column chromatography on silica gel (DCM/MeOH = 20/1) 
to afford 8 as a brown solid (1.41g, 73 %). 1H NMR (CDCl3, 300 MHz):  8.19 (d, J = 9.0 Hz, 
1H), 8.09 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 6.0 Hz, 2H), 7.29-7.21 (m, 5H), 7.07 (t, J = 7.5 Hz, 2H), 
7.00-6.92 (m, 3H), 5.39 (s, 2H), 5.32 (s, 2H), 4.78 (s, 2H), 3.02 (s, 6H), 1.31 (s, 9H); 13C NMR 
(CDCl3, 75 MHz): δ 149.4, 142.3, 138.6, 136.2, 133.4, 130.3, 129.1, 128.9, 128.4, 127.9, 127.6, 
126.1, 124.8, 123.9, 120.1, 115.2, 107.9, 85.1, 66.9, 58.8, 48.1, 32.8, 27.5.; HRMS (ESI+): 
Calculated (m/z) for C30H35N2O2 [M]








A solution of 7 (500 mg, 1.01 mmol), N-(diphenylmethylene) glycine tert-butyl ester (300 mg, 
1.01 mmol) and O-allyl-N-(9-anthracenylmethyl) cinchonidinium bromide PTC (123 mg 0.203 
mmol) in dry DCM (10 mL) was maintained at -20 °C for 30 minutes. 50% aqueous KOH (86 mg, 
15 mmol) was added to the reaction by maintaining the temperature -20 °C. Reaction was stirred 
vigorously with mechanical stirrer for 72 h. After consumption of the starting material, as judged 
by TLC, water was added, and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over anhydrous Na2SO4; the solvent was evaporated in vacuo. 
The residue was purified with flash column chromatography on silica gel (hexane/EtOAc = 20/1) 
to afford 9 as a light brown solid (326 mg, 65%). 1H NMR (CDCl3, 300 MHz):  7.75 (s, 1H), 
7.62 (d, J = 9.0 Hz, 2H), 7.37-7.28 (m, 3H), 7.23-7.20 (m, 3H),  7.06 (q, J = 9.0 Hz, 3H), 6.91 (t, 
J = 9.0 Hz, 1H), 6.41 (d, J = 6.0 Hz, 2H), 5.10 (t, J = 6.0 Hz, 1H), 4.26 (dd, J = 10.5 Hz, 4.5 Hz, 
1H), 3.39 (dd, J = 19.5 Hz, 4.5 Hz, 1H), 3.28 (dd, J = 15.0 Hz, 9.0 Hz, 1H), 1.68 (s, 3H), 1.65 (s, 
3H), 1.48 (s, 9H); 13C NMR (CDCl3, 75 MHz): δ 171.5, 169.6, 139.5, 136.0, 135.5, 134.9, 134.3, 
129.9, 129.2, 128.7, 127.8, 127.7, 127.6, 120.8, 120.6, 119.0, 118.4, 110.0, 107.2, 80.8, 66.7, 28.1, 
27.9, 25.7, 25.1, 17.7; HRMS (ESI+): Calculated (m/z) for C33H37N2O2 [M+H]
+: 493.2850, 
Found: 493.2845. HPLC: 93% ee, Chiralcel OD column (25 cm x 0.46 cm, ID), 2 % i-PrOH in 





(S)-tert-butyl 2-amino-3-(2-(3-methylbut-2-en-1-yl)-1H-indol-3-yl) propanoate (10) 
 
 
     A solution of 9 (200 mg, 0.41 mmol) THF (6 mL) and 1N hydrochloric acid (4 mL) was 
maintained in cold water bath for 2 h under nitrogen atmosphere. After consumption of the starting 
material, as judged by TLC analysis, the mixture was extracted with hexane (3 x 5 mL) then the 
aqueous layer was basified using saturated NaHCO3 and extracted with CH2Cl2 (3 x 5 mL), washed 
with brine (1 x 5 mL). The combined organic layer was dried over anhydrous MgSO4 and the 
solvent was evaporated under in vacuo. The crude product was purified by silica gel column 
chromatography (DCM/MeOH = 20:1) to afford 10 as a light yellow solid (126 mg, 95% yield). 
1H NMR (CDCl3, 300 MHz):  8.52 (brs, 1H), 7.59 (d, J = 9.0 Hz, 1H), 7.26 (d, J = 6.0, 1H), 
7.15-7.08 (m, 2H), 5.34 (t, J = 7.5 Hz, 1H), 3.75 (dd, J = 9.0, 3.0 Hz, 1H), 3.49 (d, J = 6.0 Hz, 
2H), 3.25 (dd, J = 15.0, 6.0 Hz, 1H), 2.91 (dd, J = 15.0, 9.0 Hz, 1H), 1.96 (brs, 2H), 1.78 (s, 6H), 
1.46 (s, 9H),; 13C NMR (CDCl3, 75 MHz): δ 174.6, 136.0, 135.4, 134.1, 128.8, 121.1, 120.7, 
119.2, 118.2, 110.6, 106.6, 81.0, 55.9, 30.5, 28.0, 25.8, 25.3, 18.0; HRMS (ESI+): Calculated 
(m/z) for C20H29N2O2 [M+H]











N-Fmoc-L-prolyl chloride (101 mg, 0.3 mmol) was dissolved in dry CHCl3 (5 mL). This solution 
was added dropwise at 0 °C to a solution of 10 (100 mg, 0.2 mmol) and triethylamine (0.106 mL, 
0.76 mmol) in dry CHCl3 (2 mL).  The mixture that resulted was stirred at 0 °C for 0.5 h, and then 
at room temperature for overnight. After consumption of the starting material, as judged by TLC 
analysis, the reaction was concentrated under reduced pressure. The residue was then dissolved in 
CH3CN (5 mL) and stirred via a stir bar until it made a homogeneous solution. To this solution 
diethyl amine (10 mL) was added dropwise to the reaction flask using an addition funnel. The 
reaction was let stir overnight and progress was monitored by TLC. The solvent was removed 
under reduced pressure and the residue was purified with column chromatography on silica gel 
(DCM/MeOH = 50/1) to afford the product 12 as a brown solid (94 mg, 76% yield). 1H NMR 
(CDCl3, 300 MHz):  8.02 (d, J = 9.0 Hz, 1H), 7.96 (s, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.28-7.24 
(m, 1H), 7.11-7.03 (m, 2H), 5.35 (t, J = 7.5 Hz, 1H), 4.72 (q, J = 7.5 Hz, 1H), 3.71 (q, J = 7.5 Hz, 
1H), 3.50 (t, J = 7.5 Hz, 2H), 3.28-3.11 (m, 2H), 3.04-2.87 (m, 2H), 2.09-1.99 (m, 1H), 1.80 (s, 
3H), 1.78 (s, 3H), 1.70-1.61 (m, 3H), 1.36 (s, 9H); 13C NMR (CDCl3, 75 MHz): δ 173.6, 171.3, 
135.7, 135.0, 134.9, 129.1, 121.0, 120.1, 119.1, 118.4, 110.3, 105.9, 81.6, 60.2, 53.5, 47.0, 30.4, 
27.9, 27.2, 25.8, 25.2, 17.9; HRMS (ESI+): Calculated (m/z) for C25H36N3O3 [M+H]
+: 426.2751, 





Synthesis of Model Compound, (S)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione (15) 
 
PyBOP (1.84 g, 3.55 mmol) and DIPEA (1.55 mL, 8.88 mmol) were added to a solution of Fmoc-
L- proline 13 (1.0 g, 2.96 mmol) and tert-butyl ester glycine (0.414 g, 2.96 mmol) in CH3CN (25 
mL). The reaction was stirred overnight, and progress was monitored by TLC. After consumption 
of the starting material, as judged by TLC analysis, the reaction was concentrated under reduced 
pressure. The residue was then dissolved in CH3CN (10 mL) and stirred via a stir bar until it made 
a homogeneous solution. To this solution diethyl amine (10 mL) was added dropwise using an 
addition funnel and the reaction was let stir overnight. Next day, the solvent was removed under 
reduced pressure and was extracted with hexane (3 x 15 mL). The residue was passed through 
flash column chromatography on silica gel (DCM/MeOH = 50/1) to afford the Fmoc removal 
dipeptide 14.  Then, the dipeptide 14 (100 mg, 0.22 mmol) was suspended in water (1 mL) and 
heated during 10 minutes at 250 °C and 150 psi, using a CEM Discover Microwave apparatus at 
250 W. The resulting suspension was filtered through a Hirsch funnel and washed with water (5 
mL), the solid was dried under high vacuum and the residue was purified with column 
chromatography on silica gel (DCM/MeOH = 50/1) to afford the product 15 as a white solid (57 
mg, 85% yield). Compound 17 was confirmed68 by comparing spectra to known NMR.  1H NMR 
(CDCl3, 300 MHz):  7.10 (s, 1H), 4.10 (d, J = 15.0 Hz, 1H), 3.90 (dd, J = 15.0, 5.0 Hz, 1H), 
3.69-3.52 (m, 2H), 2.42-2.34 (m, 1H), 2.14-2.01 (m, 2H), 1.95-1.87 (m, 2H). 13C NMR (CDCl3, 





Synthesis of Tryprostatin B (16) 
 
The dipeptide product 13 (50 mg, 0.12 mmol) was suspended in water (1 mL) and heated for 10 
minutes at 250 °C and 150 psi, using a CEM Discover Microwave apparatus at 250 W.  The 
resulting suspension was filtered through a Hirsch funnel and washed with water (5 mL). Then, 
the solid was dried under high vacuum and the residue was purified with column chromatography 
on silica gel (DCM/MeOH = 50/1) to afford the product 1 as yellow solid (33 mg, 81% yield). 
Compound 1 was confirmed52 by comparing spectra to known NMR. 1H NMR (CDCl3, 500 
MHz):  8.03 (brs, 1H), 7.50 (d, J = 10.0 Hz, 1H), 7.34 (d, J = 5.0 Hz, 1H), 7.18 (t, J = 7.5 Hz, 
1H), 7.12 (t, J = 7.5 Hz, 1H), 5.66 (s, 1H), 5.33 (t, J = 7.5 Hz, 1H), 4.39 (dd, J = 10.0, 5.0 Hz, 1H), 
4.08 (t, J = 7.5 Hz, 1H), 3.72-3.67 (m, 2H), 3.63-3.59 (m, 1H), 3.49 (t, J = 7.5 Hz, 2H), 3.00-2.91 
(m, 1H), 2.38-2.33 (m, 1H), 2.08-2.02 (m, 2H), 1.96-1.90 (m, 1H), 1.81 (s, 3H), 1.78 (s, 3H); 13C 
NMR (CDCl3, 125 MHz): δ 169.4, 165.8, 136.4, 135.5, 135.4, 128.0, 121.9, 119.9, 119.7, 117.8, 
110.8, 104.7, 59.3, 54.6, 45.4, 28.4, 25.8, 25.6, 25.1, 22.7, 18.0; HRMS (ESI+): Calculated (m/z) 
for C21H26N3O2 [M+H]








Tert-butyl 3-((dimethylamino)methyl)-6-methoxy-1H-indole-1-carboxylate (18) 
 
 
A solution of Boc anhydride (Boc2O) (2.6.0 g, 14.7 mmol), 4-dimethylaminopyridine (DMAP) 
(0.12 g, 0.98 mmol), trimethylamine (TEA) (0.120 mL, 1.17 mmol) in THF (50 mL) was 
maintained at 0 °C for 30 min. A solution of 6-methoxy gramine (2.0 g, 9.8 mmol) in THF (15 
mL) was added dropwise through the dropping funnel over a period of 30 min at 0 °C. The reaction 
mixture was stirred at 0 °C for 1.5 hours under nitrogen atmosphere. After consumption of starting 
material, as judged by TLC analysis, water (20 mL) was added to the reaction mixture. The 
aqueous layer was extracted with ether (3 x 15 mL), washed with brine (1 x 15 mL). The combined 
organic layer was dried over anhydrous Na2SO4. The crude product was purified with column 
chromatography on silica gel (hexane/EtOAc = 3/2) to give product 18 as a light brown solid (2.8 
g, 94%). 1H NMR (CDCl3, 300 MHz):  7.76 (s, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.39 (s, 1H), 6.88 
(d, J = 9.0 Hz, 1H), 3.86 (s, 3H), 3.49 (s, 2H), 2.27 (s, 6H), 1.66 (s, 9H); 13C NMR (CDCl3, 75 
MHz): δ 157.9, 149.8, 136.6,  124.3, 123.0, 120.2, 118.1, 111.9, 99.3, 83.2, 55.5, 54.7, 45.5, 28.2; 
HRMS (ESI+): Calculated (m/z) for C17H25N2O3 (M+H)










N,N,3-trimeth -ylbut-2-en-1-aminium bromide (19) 
 
A solution of Boc-protected 6-methoxy gramine 18 (2.0 g, 6.6 mmol) in THF (25 mL) was taken 
in three necked round bottomed flask and nitrogen was bubbled through the solution for 20 min. 
This mixture was cooled to -78 °C and n-butyl lithium (5.3 mL, 2.5 M, 13.2 mmol) was added 
dropwise to the reaction mixture maintaining a temperature -78 °C over a period of 1 h under 
nitrogen atmosphere. Prenyl bromide (3.0 mL, 26.3 mmol) was added to the reaction dropwise 
through the dropping funnel over a period of 30 min. The reaction mixture was allowed to warm 
to room temperature and was stirred overnight. After consumption of the starting material, as 
judged by TLC analysis, water (20 mL) was added to the reaction mixture and THF was removed 
under reduced pressure. The mixture was then extracted with CH2Cl2 (3 x 15 mL), the combined 
organic layers were washed with brine solution (1 x 10 mL) and dried over anhydrous Na2SO4 and 
evaporated in vacuo to obtain crude product. The residue was purified with flash column 
chromatography on silica gel (DCM/MeOH = 20/1) to afford 19 as a brown solid (2.9 g, 85 %). 
1H NMR (CDCl3, 300 MHz):  7.94 (d, J = 9.0 Hz, 1H), 7.57 (s, 1H), 6.82 (t, J = 6.0 Hz, 1H), 
5.31 (t, J = 7.5 Hz, 1H), 5.07 (s, 2H), 4.95 (s, 1H), 4.42 (d, J = 6.0 Hz, 1H), 3.75 (s, 6H), 3.05 (s, 
6H),  1.80 (s, 3H), 1.76 (s, 3H), 1.67 (s, 3H), 1.57 (s, 12H); 13C NMR (CDCl3, 75 MHz): δ 157.7, 
149.7, 148.7, 142.6, 136.9, 133.9, 122.8, 120.6, 120.4, 112.5, 111.2, 106.0, 99.6, 84.9, 61.8, 58.3, 
55.5, 48.3, 27.8, 26.8, 26.4, 25.4, 19.4, 18.6; HRMS (ESI+): Calculated (m/z) for C27H41N2O3 






indol-3-yl)- 1H-indol-3-propanoate (2) 
 
A solution of C2, N-diprenylated-6-methoxy gramine salt 19 (1.0 g, 1.9 mmol), N-
(diphenylmethylene) glycine tert-butyl ester (680 mg, 2.3 mmol) and tetrabutylammonium 
bromide (232 mg 0.383 mmol) in dry DCM (10 mL) was maintained at -20 °C for 30 minutes. 
50% aqueous KOH (1.0 g, 19.0 mmol) was added to the reaction by maintaining at the room 
temperature. Reaction was stirred vigorously with mechanical stirrer for 12 h. After consumption 
of the starting material, as judged by TLC, water was added, and the aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4; the 
solvent was evaporated in vacuo. The residue was purified with flash column chromatography on 
silica gel (hexane/EtOAc = 20/1) to afford as a light yellow solid 20 (820 mg, 82%). 1H NMR 
(CDCl3, 300 MHz):  7.75 (d, J = 6.0 Hz, 3H), 7.35-7.31 (m, 2H), 7.26-7.20 (m, 3H), 7.07 (t, J = 
7.5 Hz , 3H),  6.77 (d, J = 3.0 Hz, 1H), 6.57 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 6.43 (d, J = 9.0 Hz, 2H), 
5.06 (t, J = 7.5 Hz, 1H), 4.21 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 3.83 (s, 3H), 3.33 (dd, J = 19.5 Hz, 4.5 
Hz, 3H), 3.22 (dd, J = 15.0 Hz, 9.0 Hz, 1H), 1.66 (s, 3H), 1.63 (s, 3H), 1.46 (s, 9H); 13C NMR 
(CDCl3, 75 MHz): δ 171.4, 169.5, 155.7, 139.5, 136.0, 135.5, 134.2, 134.1, 129.9, 128.7, 127.8, 
127.7, 127.6, 123.7, 120.8, 119.0, 108.4, 107.1, 94.2, 80.8, 66.7, 55.8, 28.1, 27.9, 25.7, 25.1, 17.7; 
HRMS (ESI+): Calculated (m/z) for C34H39N2O3 [M+H]









A solution of 20 (500 mg, 0.96 mmol) THF (10 mL) and 1N hydrochloric acid (5 mL) was 
maintained in cold water bath for 2 h under nitrogen atmosphere. After consumption of the starting 
material, as judged by TLC analysis, the mixture was extracted with hexane (3 x 10 mL) then the 
aqueous layer was basified using saturated NaHCO3 and extracted with CH2Cl2 (3 x 10 mL), 
washed with brine (1 x 5 mL). The combined organic layer was dried over anhydrous MgSO4 and 
the solvent was evaporated under in vacuo. The crude product was purified by silica gel column 
chromatography (DCM/MeOH = 20:1) to afford 21 as a light yellow solid (307 mg, 90% yield). 
1H NMR (CDCl3, 300 MHz):  7.87 (brs, 1H), 7.44 (d, J = 5.0 Hz, 1H), 6.82 (s, !H), 6.77 (d, J = 
5.0, 1H), 3.84 (s, 3H), 3.68 (d, J = 10.0 Hz, 1H), 3.47 (d, J = 10.0 Hz, 2H), 3.18 (dd, J = 15.0, 5.0 
Hz, 1H), 2.85 (dd, J = 15.0, 10.0 Hz, 1H), 1.79 (s, 3H), 1.77 (s, 1H), 1.44 (s, 9H),; 13C NMR 
(CDCl3, 75 MHz): δ 174.7, 155.9, 136.0, 134.4, 134.4, 123.3, 120.6, 118.9, 108.7, 106.7, 94.6, 
80.9, 55.9, 55.8, 30.6, 28.0, 25.8, 25.2, 17.9; HRMS (ESI+): Calculated (m/z) for C21H31N2O3 
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2.1.1. Histone  
Histones are most abundant highly alkaline proteins found in eukaryotic cell nuclei.1,2 Five major 
families of histones are H1/H5, H2A, H2B, H3, and H4. Histones H2A, H2B, H3 and H4 are 
known as the core histones, while histones H1/H5 are known as the linker histones.3-5 Histone 
H2A and H2B make a dimer and later dimer of dimer, and H3 and H4 make dimer and later 
tetramer, all these core histones then combine and form octamer of histones.6-8 This histone 
octamer rapped by deoxyribonucleic acid (DNA) and makes nucleosome.9 They are the chief 
protein components of chromatin and playing a role in gene regulation. This interaction is largely 
regulated by the modification of lysine residues.10 
 
2.1.2. Histone Deacetylase (HDAC) 
Histone deacetylases (HDAC), also called lysine deacetylases (KDAC), are a class 
of enzymes which eliminate acetyl groups (O=C-CH3) from an N-acetyl lysine amino acid on 
a histone, permitting the histone to wrap the DNA more strongly.11-15 Its action is opposite to that 
of histone acetyltransferase (HAT) which replace acetyl groups (O=C-CH3) to the lysine amino 
acid on a histone.16-20 Acetyl CoA transfers the acetyl group to the lysine terminal of the histone 
(Figure 2.1).21-25 Acetylation/deacetylation process is important because it regulates many protein 
functions in cells.26-30 DNA is wrapped around histones, and DNA expression, protein stability, 
and protein-protein interactions are regulated by acetylation and de-acetylation.31-35 HAT/HDAC 
inhibition and posttranslational modifications are essential for the regulation of many cellular 







Figure 2.1: Mode of Action of HDAC and HAT  
 
HATs and HDACs enzymes are responsible for amendments to chromatin structures that can 
regulate gene transcription.41-45 In general, HAT acetylation activity leads to an increase in gene 
transcription by neutralizing the positive charge on lysine residuals of histones, which relaxes their 
interactions with the negatively charged DNA backbone, leading to form a more active chromatin 
framework.46, 47 In contrast, HDACs catalyze the removal of the acetyl groups on lysine residuals 
located on the amino-terminal tails of core histones, which leads to gene repression by chromatin 
condensation, leading to form an inactive chromatin framework.48 As a result, inhibition of HATs 
leads to a gene that is always deactivated and produced oncogene, while inhibition of HDACs 
leads to general hyperacetylation of histones, which is followed by the transcriptional activation 
of certain genes through relaxation of the DNA conformations and produced antioncogene.49-52 
Usually, cancer is considered to initiate from a wide variety of genetic and genomic modifications, 
such as mutations, deletions, rearrangements, and amplifications, leading to abnormal expression 
of tumor suppressor genes and oncogenes. Gathering evidence indicates that cancer is associated 
with abnormal cell functions that include apoptosis, autophagy, cell motility, and DNA repair. 





2.1.3. Classification of HDAC proteins 
Based on their size, number of catalytic sites, subcellular localization, and their sequence 
homology to yeast counterparts, there are total eighteen known human HDACs proteins that are 
divided into four classes (Figure 2.2).57 HDACs 1, 2, 3 and 8 are classified as Class I which are 
found in nucleus, HDACs 4, 5, 7, and 9 are classified as Class IIa and found in nucleus and 
cytoplasm. HDACs 6 and 10 are classified as Class IIb and found in cytoplasm. HDAC 11 is 
known as class IV and found in both nucleus and cytoplasm. All these HDACs are Zn2+ dependent 
enzymes. Class III proteins, also known as sirtuins, (SIRTs 1–7) are defined by their dependency 
on the coenzyme, electron transporter, nicotinamide adenine dinucleotide (NAD+), found in 
nucleus and cytoplasm.58-60  
 
Class Name Location in Cell Location in Body Group 
 
Class I HDAC1 Nucleus Ubiquitous Zn Dependent 
 HDAC2    
 HDAC3    
 HDAC8    
 
Class IIA HDAC4 Nucleus/Cytoplasm Tissue Zn Dependent 
 HDAC5    
 HDAC7    
 HDAC9    
 
Class IIB HDAC6 Cytoplasm Tissue Zn Dependent 
 HDAC10    
 
Class III SIRT (1-7) Nucleus/Cytoplasm Tissue NAD Dependent 
 
Class IV HDAC11 Nucleus/Cytoplasm  Zn Dependent 
 






2.1.4. HDAC Involvement with Different Types of Cancers and Memory Loss 
Cancer is a group of diseases involving abnormal cell growth which is a complex process that is 
influenced by multiple factors and progresses in multiple steps.61 This unwanted cell growth in 
one place spreads out to other parts of the body. A typical characteristic of human cancer is the 
deregulation of histone acetylation which has the fatal consequence of gene transcription.62 The 
decrease of histone acetylation is the reason for cancer, for example gastrointestinal tumors. It is 
well established and reported by scientists that the acetylation/deacetylation state of histones has 
an important effect on the biological activity of a cell.63 Any imbalance in the levels of 
acetylation/deacetylation can encourage abnormal outgrowth and cell death. HDACs are expressed 
at much higher rates than normal cells in numerous types of cancers. Due to the overexpression of 
HDAC, it creates different types of cancer such as prostate, ovarian (HDAC1, HDAC2, and 
HDAC3), colorectal, lung cancers (HDAC1 and HDAC3), gastric pancreatic (HDAC2) and 
hepatocellular carcinomas. The overexpression is only found in cancer cells, but are not found in 
normal, resting endothelial cells and normal organs.64 Solid and hematological tumors are the 
cause of unusual expression of classical (class I, II, and IV) HDACs. HDACs has been connected 
to a variety of malignancies, including with advanced disease and poor outcomes in patients. It has 
been reported that high expression of HDAC1, 2, and 3 are related with poor outcomes in gastric 
and ovarian cancers, and high expression of HDAC8 correlates with advanced-stage disease and 
poor survival in neuroblastoma. HDACs have also been found broadly dysregulated in multiple 
myeloma (MM) and overexpression of class I HDACs, particularly HDAC1, is associated with 
inferior patient outcomes.65 HDAC2 and 3 are responsible for blocking neural plasticity and impair 






2.2. HDAC Inhibitors 
Over the last decade, there has been extensive research and devolvement of many HDACi which 
has led to very promising results in treating cancer cells and other various diseases.69-83 Several 
HDACi drugs are in clinical trials for treatment of cancers and diseases (Figure 2.3).84-89 The first 
HDACi, suberoyl anilide hydroxamic acid (SAHA, Vorinostat) was approved by the Food and 
Drug Administration (FDA) for treatment of T-Cell lymphoma (CTCL) in the early 2000s.90-93 
Then, in 2009 the FDA approved romidepsin/FK-228 also for CTCL.94-96 SAHA is considered to 
be a pan-inhibitor, which means it has no selective to any class or specific HDAC protein and 
inhibits the majority of the 11-zinc dependent HDAC isoforms. However, FK-228 is considered a 
class I selective inhibitor (inhibiting only HDAC1 and HDAC2). Valoproic acid and trichostatin 




Target HDAC Class Clinical Status 
Hydroxamic 
Acids 
Trichostatin A Pan Inhibitor Preclinical 
 
SAHA Pan Inhibitor Approved for Cutaneous T-Cell 
Lymphoma 
 
Belinostat Pan Inhibitor Approved for Cutaneous T-Cell 
Lymphoma 
 




Valproic Acid HDAC1 and 
HDACIIA 
Approved for Epilepsia, Bipolar 
Disorders, and Migrane 
 




Romidepsin HDAC1 Approved for Cutaneous T-Cell 
Lymphoma 
 





There are many different types of HDAC inhibitors but the four most promising classes of HDACi 
are usually classified based on their chemical structure such as 1) hydroxamic acids, 2) cyclic 
peptides, 3) short-chain fatty acids, and 4) benzamide/ketone derivatives (Figure 2.4).99-108 
 
 
Figure 2.4: Types of HDAC Inhibitors 
 
All the four groups of HDAC inhibitors have similar trends structurally. The structure of HDACi 
are characterized by these main features: a coordinating group/zinc binding group (ZBG) (such as 
a thiol or hydroxamic acid) to chelate to Zn2+ in the active site, a hydrophobic region (capping 
group), and a five to seven carbon linker that connects the cap group to ZBG (Figure 2.5). In 
HDAC inhibitors, linker connects a cap region and a ZBG.109-123 The cap is relatively flexible and 
mediates surface-to-surface interactions between drug and protein target; the ZBG is critical for 





2.2.1. Mechanism of HDAC Inhibition 
To understand how HDAC inhibitors bind to their enzymes, the first experiments were carried out 
to study in 1999.152 The structure of the complexes of TSA and SAHA with histone deacetylase-
like protein were clearly measured to 2.0 angstroms (Å) resolution. For further development of 
more potent and specific HDAC specific inhibitors, analysis of the X-ray crystal revealed that the 
region interacting with TSA or SAHA of histone deacetylase-like protein contains three main 
features 1) a surface recognition section, 2) a tube-like, 11 Å deep channel, and 3) a 14 Å long, 
tapered pocket which attaches to the channel.153 Structure-activity relationship showed that 
inhibitors such as TSA and SAHA were able to block the HDAC activity through chelation of the 
zinc ion using a polar moiety such as hydroxamic acid or benzamide groups and in the similar 
way, romidepsin FK228 were able to block the HDAC activity through chelation of zinc ion using 
thiol group.154 HDAC inhibitors are one of the most promising targets for the development of anti-
cancer drugs. Results from several studies and market demand of drugs have encouraged further 
development of more HDAC inhibitors for use in cancer therapy.155 HDAC inhibitors have been 
used in many clinical trials for that can target both hematological and solid malignancies are in 
progress. However, the mechanism of action by which they are employed to the HDAC pocket 
and mediate corresponding cellular activities is still mysterious. A better understanding of the 
nature of the molecular basis of the selectivity of the HDAC inhibitors will enable the development 









2.2.2. Shortfalls and solution of current drugs 
Current HDAC inhibitors used in cancer are toxic with many side effects to patients. They have 
lack specificity and affect several types of HDAC, and they have poor solubility.159, 160 In order to 
obtain new compound derivatives or fragments that could reduce cytotoxicity but still retain 
adequate HDAC inhibitory activity as well as antitumor activity, we thought we would design 
some compounds which would be less toxic, more soluble, and better specificity toward specific 
HDAC types. Our goal was to synthesize small molecules which will be easy to synthesize from 
inexpensive commercially available starting materials.  New analogs would have promising effects 
on cervical cancer, breast cancer, colon cancer, prostate cancer, and renal cancer cell lines. To 
keep thiol group as binding site, our group designed some amide compounds as HDAC inhibitors 
based on the Romidepsin, FK228 (Figure 2.6). 
 
 






2.3. Cell lines, Reagents, and Animals 
A human prostate cancer line (DU145) purchased from ATCC (Manassas, VA) and cultured in 
DMEM medium (Life Technologies, Grand Island, NY), supplemented with 10% fetal bovine 
serum (Atlanta Biologicals, Flowery Branch, GA), 100 U/ml penicillin, 100 μg/ml streptomycin 
and 2mM L-Glutamine (all from ThermoFisher Scientific) in Dr. Douglas Steeber’s laboratory. 
Cell counts and viability were determined using a hemocytometer following appropriate dilution 
in trypan blue exclusion dye. The 4T1 cells were grown in RPMI 1640 media that was 
supplemented as above along with addition of 55 μM 2-mercaptoethanol (Life Technologies, 
Grand Island, NY). Cpd1’ and Cpd5 were synthesized and purified by high performance liquid 
chromatography (HPLC) as described. The food and drug administration (FDA)-approved drugs 
romidepsin (FK228) were purchased commercially (Selleckchem, Houston, TX) and used as 
positive controls for comparison purposes. Dimethyl sulfoxide (DMSO, ThermoFisher) was used 
to dissolve the drugs and served as vehicle controls for all experiments. 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma Aldrich and was used as 
a colorimetric reagent to determine cell proliferation. Live cells actively convert MTT into a purple 
insoluble formazan product, while dead cells do not, and this change can be measured 
spectrophotometrically after being dissolved in DMSO. Wild type BALB/c mice and C57BL/6J 
(B6) mice were originally purchased from the Jackson Laboratories (Bar Harbor, ME) and further 
housed and bred in a specific pathogen-free facility at the University of Wisconsin-Milwaukee and 
screened regularly for pathogens. Mice behavioral study for Alzheimer’s disease was done in Dr. 
Karyn Frick’s laboratory. All procedures were approved by the Animal Care and Use Committee 






2.3.1. MTT Cellular Assay 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a yellow tetrazole is 
reduced to purple formazan in living cells, shows the color after the assay where increasing 
amounts of cells resulted in increased purple coloring (Figure 2.7).161 For the assay, cells were 
allowed to adhere for 24 hours at 37 °C with 5% CO2. All of the synthetic compounds, FK228, 
and DMSO control concentrations were diluted in series with supplemented Dulbecco’s Modified 
Eagle Medium (DMEM) sterilely. The media was aspirated off the 96 well plate and the drug, or 
control, concentrations were added to the plate in triplicate. The cells were then incubated with the 
drugs or DMSO controls for 48 hours. The drug and control treatments were removed and 200 
µg/mL of MTT diluted in supplemented DMEM was added to each well. Cells were incubated 
with the MTT for 4 hours at 37 °C with 5% CO2. The MTT concentration was aspirated off and 
200 µL DMSO was added to each well after 4 hours. The plate was mixed on a rotator for 10 
minutes at a moderate pace and then with a pipettor to dissolve all the MTT in each well. The plate 
was read at 570 nM with the reference wavelength at 690 nM on a Molecular Devices Versamax 
plate reader (San Jose, CA). The reference wavelength absorbance for each well was subtracted. 
The average for the triplicate blank wells was calculated and subtracted from each well. The % 
viability of each concentration was calculated by dividing the average absorbance for each drug 
concentration by the DMSO control for that concentration. 
 





2.3.2. H3 Acetylation Assay 
For H3 acetylation assay, DU145 cells were cultured as above. Cells were counted and 
resuspended at 60,000 cells/mL in supplemented DMEM. 1 mL of cells at 60,000 cells/mL were 
added to wells of a 24 well plate. The cells were allowed to adhere for 24 hours at 37 °C with 5% 
CO2. The media was aspirated and Cpd 1’ at 50, 5, or 0.5 μM concentrations, or DMSO controls, 
in supplemented DMEM were added to the wells in duplicate. The plate was incubated at 37 °C 
with 5% CO2 for 24 hours. Cells were fixed with 350-500 μL 4% paraformaldehyde for 10 minutes 
at room temperature after the 24-hour incubation. 400-500 μL tris-buffered saline (TBS) with 0.1% 
Tween 20 and 1% bovine serum albumin (TBS-T w/ 1% BSA) was added to each well for 1 hour 
at 4 °C for permeabilization. TBS-T w/ 1% BSA was removed and 350 to 500 μL rabbit anti-
acetyl-Histone H3 (Lys9/Lys14) antibody (Cell Signaling Technology, Danvers, MA) at a 1:2000 
dilution in TBS-T w/1% BSA was added to each well. The primary antibody was incubated with 
the cells overnight at 4 °C. The primary antibody was removed and goat anti-rabbit IgG 
AlexaFluor™ 488 (Jackson ImmunoResearch, West Grove, PA) at a 1:500 dilution was added to 
each well and incubated for 1.5 hours at 4 °C. The Plate was removed from the fridge and 350-500 
μL of 4′,6-diamidino-2-phenylindole (DAPI) at 0.3 μg/mL was added to each well. DAPI was 
incubated in dark at room temperature for 15 minutes, and wells were imaged with the fluorescence 
microscope (Figure 2.8).162 
 





2.3.3. Memory Enhancement Study 
The present study was designed to evaluate the effect of our synthetic compound on memory of 
mice for Alzheimer’s disease. Mice were housed in a conventional animal vivarium and were given 
free access to food and water. All studies and procedures were approved by the Animal Care and 
Use Committee of the University of Wisconsin, Milwaukee. Each animal was initially weighed 
using a digital scale and then intraperitoneally (IP) injected with the compounds. The effects on 
hippocampal memory in rodents was assessed in spatial tasks such as object location/placement 
and in object recognition tasks.163 Effect of drugs on learning and memory of mice was evaluated 
by these behavioral study as well as by IP injection. From the study is has been shown that our 
drug has significant effect and drugs found in hippocampus study. Hippocampus is a small portion 
on the brain which develop the memory (Figure 2.9). A single mouse was given a single IP dose 
of 40 mg/kg, body weight and a second mouse received a dose of 20 mg/kg. Later, brains were 
collected, separated the hippocampus, and mass of the compound was investigated by single 
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2.4. Results and Discussion 
2.4.1. Results from MTT Assay 
One of our synthetic compounds were found to be active against prostate cancer cell line. We 
performed MTT assay, a colorimetric assay for assessing cell metabolic activity, reflects the 
number of viable cells present. MTT, a yellow tetrazole, is reduced to purple formazan in living 
cells and increasing amounts of cells resulted in increased purple coloring. Cpd 1, Cpd 1’, Cpd 5, 
and Cpd 5’ were tested for MTT assay with DU-145 prostate cancer line. The result showed that 
Cpd 1, Cpd 5 and Cpd 5’ are not active which were shown from the cell viability. The cell viability 
















When our synthetic compounds were not active, we thought this is due to the purity. To make 
purer, the mixture was first purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 um, 
Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and the detection wave length was set 
at 210 nm. The peak was collected at 8-12min. Then this peak was injected in HPLC (Varian 
ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % ACN/H2O was used 


















We separated two diestereoisomers of our synthetic compounds by silica gel column 
chromatography. After collecting pure product, activity of the compounds were tested, and this 
















Figure 2.12: Activity Measurement by Cell Viability of Diastereomers A and B of Cpd 5 
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When Cpd 1, Cpd 5, and Cpd 5’ did not show any activity against, we tested Cpd 1’ for the same 
assay with similar line. Surprisingly we found that Cpd 1’ has activity in MTT assay (Figure 2.13). 
When 3.1 M solution of Cpd 1’ was used for the assay, it showed there was no cell death, all cells 
are viable. The statement was almost true for 6.2 M and 12.5 M solution of Cpd 1’, cells are 
viable 90% and 80%, respectively. When 25M solution was tested it was found that 1lmost 80% 




Figure 2.13: Activity of Cpd 1’ in DU-145 Prostate Cancer Cell Line 
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2.4.2. Results from H3 Acetylation Assay 
We found that Cpd 1’ is active, and more than 80% cell are dead in MTT assay. But we wanted to 
make sure the cell death is due to our synthetic compound or other reason. To make sure our 
compound is active, and it can acetylase the histones, we performed H3-acetylation assay. From 
the H3-acetylation assay, we confirmed that our synthetic compound Cpd 5 and Cpd 5’ are not 
active in H3-acetylation assay (Figure 2.14). All results are compared with DMSO control, and 
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In H3-acetylation assay, Cpd 1 and Cpd 1’ were also tested and found that Cpd 1’ is also active 
in this assay (Figure 2.15). All results are compared with DMSO control, and blue colors are 
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When it was shown that Cpd 1’ was active and it acetylated the histone in 50 solution, then it was 
also tested with lower concentration of Cpd 1’. All the results are compared with market drug FK 
228 (Figure 2.16). It was found that Cpd 1’ had medium acetylation with the concentration 12.5 
M and 25 M. Deep green color indicated that higher acetylation, and light green indicated 
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2.4.3. Results from In-Vivo Studies 
Our synthetic compound 1’ was also tested for memory enhancement study in mice. It is known 
that if the compound enters the hippocampus of the brain and inhibit HDAC activity, then memory 
enhancement could occur. Because HDAC 2 and HDAC 3 blocks neural plasticity and impair 
memory. From the behavioral study of mice and in vivo test, it was shown that our compound can 
increase the memory. It was found from the ip injection of mice that; our compound was present 
in the hippocampus for 10 min with 40 mg/kg and 20 mg/kg dose respectively (Figure 2.17). Our 

















It was also found from the ip injection of mice that; our synthetic compound Cpd 1’ was present 
in the other parts of the brain for in vivo 10 min with 40 mg/kg and 20 mg/kg dose respectively 
(Figure 2.18). Our synthetic compound was identified with respect to internal standard 4, 5-
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Several in vivo studies were done with our synthetic compound, Cpd 1’ was done with the 
collaboration of Biology department and Psychology Department. All the in vivo studies are found 
to be positive.  The compound is detectable in blood, brain, and liver (Figure 2.19). Our synthetic 
compound was identified with respect to internal standard 4, 5-diphenyl imidazole which are 

























The plasma stability assay (PSA) is to measure the degradation of compounds in plasma. This is 
the in vitro absorption, distribution, metabolism, and elimination (ADME) screening system. It 
was also found from PSA study that our synthetic compound Cpd 1’ was present it was found that 
our compound is stable with 8.9 hours half-life (Figure 2.20). 
 
 

























In conclusion, histone deacetylase inhibitors are an exciting new class of medicines with broad 
applications. We synthesized a set of compounds based on the scaffold of the FK228 in our lab, 
among them Cpd 1’ was found to be active against DU-145 prostate cancer cell line. 
Comprehensive pharmacokinetic studies, more behavioral study on mice are currently underway. 
Our group has been making different analogs of Cpd 1’as well as the modification of Cpd 1’ to 
have a most active compound as anti-cancer agent as well Alzheimer’s disease. 
 
 
Our group has been planning to make a best drug by the following changes in future; 
1. By making the monomer of our synthetic compound Cpd 1’ 
 
 
2. By the reduction of double for making the longer chain of Cpd 1’ 
  
 







2.6. General Methods and Experimental 
2.6.1. General Consideration  
All reactions were performed under a dry nitrogen atmosphere using standard Schlenk techniques 
unless otherwise noted.  All reaction vessels were flame dried under vacuum and filled with 
nitrogen prior to use. Reagents and solvents were purchased from Sigma-Aldrich, Milwaukee. All 
1H and 13C NMR spectra were recorded in CDCl3 (internal standard: 7.26 ppm, 
1H; 77.16 ppm, 
13C) at room temperature with a Burker 300 MHz and 500 MHz spectrometers. The chemical shifts 
(δ) are given in parts per million (ppm) and the coupling constants in Hertz (Hz). The following 
abbreviations are used: s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet. Previously reported 
compounds were identified by 1H NMR. All new compounds were additionally characterized by 
1H NMR, 13C NMR and high-resolution mass spectrometry (HRMS). HRMS were obtained using 
electrospray ionization (ESI) technique. For column chromatography, silica gel (35-70 microns) 
was used. Thin layer chromatography (TLC) was performed on aluminium backed plates pre-
coated (0.25 mm) with Silica Gel 60 F254 with a suitable solvent system and was visualized using 
UV fluorescence and/or iodine chamber. The crude reaction mixture was first purified by Hi-Flash 
Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was collected at 8-12min. 
Then this peak was injected in the high-performance liquid chromatography (HPLC) (Varian 
ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O was used 








3-(Tritylthio)propanal, 3:  
 
A round bottom flask was charged with triphenylmethanethiol (5.0 g, 18.1 mmol).  The flask was 
put under argon and the contents of the flask were dissolved in dichloromethane (50 mL).  
Triethylamine (3.0 mL, 21.7 mmol, 1.2 equiv.) was added to the mixture and was stirred for 
additional 10 minutes. Acrolein (1.2 mL, 18.1 mmol) was added to the mixture dropwise and was 
stirred for 2 hours and was then concentrated in vacuo.  The crude product was purified by flash 
column chromatography with a 25% ethyl acetate/hexane solution until the product spot eluted. 
The product, 3-(tritylthio)propanal was purified by recrystallization with toluene and collected 5.3 
g with 88% yield 3. Compound 3 was confirmed164 by comparing spectra to known NMR. 1H 
NMR (CDCl3, 500 MHz): δ (ppm) 9.59 (s, 1H), 7.47 (d, J = 10.0 Hz, 6H), 7.47 (q, J = 7.5 Hz, 
6H), 7.26 (t, J = 5.0 Hz, 3H), 2.51 (t, J = 7.5 Hz, 2H), 2.41 (t, J = 7.5 Hz, 2H); 13C NMR (CDCl3, 




A round bottom flask was charged with 3-(tritylthio)propanal (5.0 g, 15.0 mmol, 1 equiv.) and 2-





the contents of the flask were dissolved in benzene (100 mL).  The solution was then refluxed 
overnight.  When all starting materials were found to be disappeared, the reaction mixture was 
allowed to cool to room temperature and was then concentrated in vacuo.  The crude product was 
separated via column chromatography and the column was run with a 20% ethyl acetate/hexane 
solution until the product spot eluted. And then the product was purified by recrystallization with 
toluene to give 3.8 g (70%) of pure product 6. Compound 6 was confirmed164 by comparing spectra 
to known NMR. 1H NMR (CDCl3, 500 MHz): δ (ppm) 9.46 (q, J = 7.5 Hz, 1H), 7.47 (d, J = 5.0 
Hz, 6H), 7.33 (d, J = 5.0 Hz, 6H), 7.26 (d, J = 5.0 Hz, 3H), 6.68-6.63 (m, 1H), 6.02 (dd, J = 15.0, 
5.0 Hz, 1H), 2.39-2.33 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 193.8, 155.8, 144.6, 133.7, 
129.6, 128.0, 126.8, 67.0, 31.8, 30.1. 
 
(E)-tert-butyl 3-hydroxy-7-(tritylthio)hept-4-enoate, 9: 
 
A round bottom flask was charged with THF (50 mL) and cooled to -78 °C under nitrogen. Later, 
diisopropylethylamine (DIPEA) (9.4 mL, 53.8 mmol, 5.5 equiv.) and n-butyllithium (21.5 mL, 
53.8 mmol, 5.5 equiv.) were added dropwise at -78°C and was stirred for 1 hour. Tert-butyl acetate 
(6.6 mL, 48.9 mmol, 5 equiv.) was added at -78°C and was allowed to stir for additional 1 hour.  
Lastly, (E)-5-(tritylthio)pent-2-enal (3.5 g, 9.8 mmol, 1 equiv.) was added and the mixture was 
stirred for 45 min at -78°C. The reaction was quenched with a saturated solution of NH4Cl (25 
mL) and then concentrated in vacuo to remove the organic solvent. Then dichloromethane was 





layer, the aqueous layer was extracted two more times with dichloromethane and the organic layers 
were combined. The organic layer was washed with NaHCO3 solution, brine, then dried over 
anhydrous Na2SO4, and concentrated in vacuo. The residue was purified with flash column 
chromatography on silica gel (ethyl acetate/ hexane, 1:9) to afford 3.6 g (78%) of product, (E)-1-
tert-butoxy-4-hydroxy-8-(tritylthio)oct-5-en-2-one as a white solid 9. 1H NMR (CDCl3, 500 
MHz): δ (ppm) 7.46 (d, J = 5.0 Hz, 6H), 7.32 (t, J = 7.5 Hz, 6H), 7.25 (t, J = 7.5 Hz, 3H), 5.64-
5.58 (m, 1H), 5.45 (dd, J = 15.0, 5.0 Hz, 1H), 4.43 (s, 1H), 3.09 (s, 1H), 2.48-2.42 (m, 2H), 2.25 
(t, J = 5.0 Hz, 2H), 2.13 (t, J = 7.0 Hz, 2H), 149 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 
171.8, 144.9, 132.1, 129.9, 129.6, 127.9, 126.6, 81.3, 68.7, 66.6, 42.4, 31.5, 31.4, 28.2. HRMS 
(ESI+): Calculated (m/z) for C30H34O3S (M+Na)
+ : 497.2121, Found 497.2129. 
 
(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid, 10:  
 
(E)-tert-butyl 3-hydroxy-7-(tritylthio)hept-4-enoate (3.0 g, 6.3 mmol, 1.0 equiv.) was dissolved in 
a 4:1 ratio of THF/water (50 mL). Next, lithium hydroxide (3.0 g, 126.5 mmol, 25 equiv.) was 
added. The solution was then heated to 50 ºC and stirred for 12 hours. The reaction was then diluted 
with water (20 mL) and then acidified to a pH of 4-5 with KHSO4. The aqueous layer was extracted 
with ethyl acetate (20 mL) four times. The organic layers were combined and washed with water, 
brine, dried over anhydrous sodium sulfate, and concentrated in vacuo.  The residue was purified 
with flash column chromatography on silica gel (ethyl acetate/ hexane, 9:10) and obtained 2.5 g 





known NMR.  1H NMR (CDCl3, 300 MHz): δ (ppm) 7.43 (d, J = 6.0 Hz, 6H), 7.30 (t, J = 7.5 Hz, 
6H), 7.25 (t, J = 6.0 Hz, 3H), 5.66-5.57 (m, 1H), 5.44 (dd, J = 15.0, 6.0 Hz, 1H), 4.48 (q, J = 6.0 
Hz, 1H), 2.56 (d, J = 6.0 Hz, 2H), 2.25 (t, J = 7.5 Hz, 2H), 2.11 (q, J = 6.0 Hz, 2H); 13C NMR 
(CDCl3, 75 MHz): δ (ppm) 177.3, 144.9, 131.6, 130.7, 129.6, 127.9, 126.7, 68.5, 66.7, 41.3, 31.4, 
31.3.  
 
(4E,4'E)-di-tert-butyl 7,7'-disulfanediylbis(3-hydroxyhept-4-enoate), Cpd 1’: 
 
Iodine (0.27 g, 2.1 mmol, 1.0 equiv.) and sodium acetate (0.17 g, 0.464 mmol, 2.0 equiv.) were 
dissolved in a 10:1 solution of CH2Cl2/MeOH (15 mL) at 0 °C. (E)-tert-butyl 3-hydroxy-7-
(tritylthio)hept-4-enoate (1.0 g, 2.1 mmol, 1.0 equiv.) was dissolved in a 10:1 solution of 
CH2Cl2/MeOH (10 mL) and was added dropwise over 20 minutes to the first solution containing 
iodine and sodium acetate. This solution was then allowed to stir for additional 2 hour. The reaction 
was quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the mixture turned 
clear. Then, brine (5 mL) was added and the phases were separated.  The aqueous layer was 
extracted with dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 mL).  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo. The crude reaction mixture 
was first purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-
20min 20-100% ACN/H2O 20ml/min and the detection wave length was set up at 210 nm. The 





the column (Prep-C18, 21.2x250 mm, 10 um) system and 70 % ACN/H2O was used to elute the 
column under the flow rate of 8 ml/min. The wavelength was set at 200 nm to detect the compound 
and 0.66 g of the pure compound Cpd 1’ was collected at 22-25 min. (68 % yield). The residue 
was purified with flash column chromatography on silica gel (hexane/ethyl acetate, 7:3) using 
triethyl amine (TEA) with similar yield. 1H NMR (CDCl3, 300 MHz): δ (ppm) 5.70-5.60 (m, 1H), 
5.48 (dd, J = 15.0, 6.0 Hz, 1H), 4.38 (q, J = 6.0 Hz, 1H), 3.3 (s, 1H), 2.64 (t, J = 7.5 Hz, 2H), 2.38-
2.31 (m, 4H), 1.38 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 171.6, 132.8, 129.1, 81.2, 68.7, 
42.5, 38.1, 31.8, 28.1. HRMS (ESI+): Calculated (m/z) for C22H38O6S2Na (M+Na)
+ : 485.2002, 
Found 485.1995. 
 
(4E, 4'E)-7,7'-disulfanediylbis(3-hydroxyhept-4-enoic acid), Cpd 1:   
 
Iodine (0.30 g, 2.4 mmol, 1 equiv.) and sodium acetate (0.20 g, 2.4 mmol, 1.0 equiv.) were taken 
in round bottomed flask and then dissolved in a 10:1 solution of CH2Cl2/MeOH (15 mL) at 0 °C. 
(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (1.0 g, 2.4 mmol, 1 equiv.) was dissolved in a 10:1 
solution of CH2Cl2/MeOH (10 mL) and was added dropwise over 20 minutes to the solution 
containing iodine and sodium acetate.  This solution was then allowed to stir for additional 2 hour.  
The reaction was quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the 
reaction mixture turned clear.  Brine (5 mL) was added and the phases were separated.  The 
aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 





residue was purified with flash column chromatography on silica gel with 100% ethyl acetate. 0.50 
g pure product Cpd 1 was obtained with 70% yield.  1H NMR (CD3OD, 300 MHz): δ (ppm) 5.80-
5.71 (m, 1H), 5.62 (dd, J = 15.0, 6.0 Hz, 1H), 4.48 (q, J = 6.0 Hz, 1H), 2.76 (t, J = 7.5 Hz, 2H), 
2.49-2.43 (m, 4H); 13C NMR (CD3OD, 75 MHz): δ (ppm) 173.7, 133.3, 128.7, 68.6, 42.1, 37.7, 
31.6.  
 
 (2S)-methyl 2-((E)-3-hydroxy-7-(tritylthio)hept-4-enamido)hexanoate, 11: 
 
(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (2.0 g, 4.8 mmol, 1 equiv.) and D-methionine methyl 
ester hydrochloride salt (0.87 g, 4.8 mmol, 1.0 equiv.) were dissolved in anhydrous 
dichloromethane (50 mL) under nitrogen. The reaction was cooled to 0 ºC and then benzotriazol-
1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (3.0 mg, 5.7 mmol, 1.2 equiv.) 
was added. The solution stirred for 20 min and then DIPEA (3.3 mL, 19.0 mmol, 4.0 equiv.) was 
added to the solution. The reaction was allowed to warm to 25 ºC and stirred for 12 hr. It was then 
quenched with a saturated NH4Cl, extracted with dichloromethane (3 x 15 mL), washed with brine, 
dried over Na2SO4, and then concentrated in vacuo. The residue was purified with flash column 
chromatography on silica gel (hexane/ethyl acetate, 3:2) and obtained 2.2 g (81%) of product 11 
as a white solid. Compound 11 was confirmed164 by comparing spectra to known NMR. 1H NMR 
(CDCl3, 300 MHz): δ (ppm) 7.43 (d, J = 10.0 Hz, 6H), 7.30 (t, J = 7.5 Hz, 6H), 7.24 (d, J = 10.0 





(m, 1H), 4.44 (s, 1H), 3.76 (s, 3H), 3.50 (s, 1H), 2.45 (dd, J = 15.0, 5.0 Hz, 1H), 2.37 (dd, J = 15.0, 
10.0 Hz, 1H), 2.24 (t, J = 7.5 Hz, 2H), 2.11 (t, J = 5.0 Hz, 1H), 1.87-1.83 (m, 1H), 1.68 (d, J = 5.0 
Hz, 1H), 1.33 (d, J = 5.0 Hz, 4H), 0.92 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 75 MHz): δ (ppm) 
173.1, 171.5, 144.9, 132.2, 130.2, 129.6, 127.9, 126.6, 69.1, 66.6, 52.4, 52.1, 42.6, 32.1, 31.5, 31.4, 
27.4, 22.3, 13.9.  
 
(2S)-2-((E)-3-hydroxy-7-(tritylthio)hept-4-enamido)hexanoic acid, 12: 
 
(2S)-methyl 2-((E)-3-hydroxy-7-(tritylthio)hept-4-enamido)hexanoate (2.0 g, 3.7 mmol, 1.0 
equiv.) was dissolved in a 4:1 ratio of THF/water (25 mL). Next was added lithium hydroxide (2.2 
mg, 91.7 mmol, 25 equiv.). The solution was then heated to 50ºC and stirred for 12 hr. The reaction 
was then diluted with 20 mL of water and then acidified to a pH of 4-5 with KHSO4. The aqueous 
layer was extracted with ethyl acetate (36 x 15 mL). The organic layers were combined and washed 
with water, brine, dried over anhydrous Na2SO4, and concentrated in vacuo.  The residue was 
purified with flash column chromatography on silica gel (ethyl acetate/hexane, 1:1) and obtained 
1.8 g (92%) of product as a white solid 12. Compound 12 was confirmed164 by comparing spectra 
to known NMR.  1H NMR (CDCl3, 300 MHz): δ (ppm) 7.43 (d, J = 10.0 Hz, 6H), 7.30 (t, J = 7.5 
Hz, 6H), 7.24 (t, J = 7.5 Hz, 3H), 6.68 (d, J = 5.0 Hz, 1H), 6.57 (d, J = 5.0 Hz, 1H), 5.61-5.56 (m, 
1H), 5.47-5.41 (m, 1H), 4.57-4.44 (m, 1H), 4.46 (t, J = 10.0 Hz, 1H), 2.46-2.36 (m, 2H), 2.23 (t, J 





(s, 1H), 0.92 (t, J = 5.0 Hz, 3H);  13C NMR (CDCl3, 75 MHz): δ (ppm) 175.6, 172.3, 146.9, 144.9, 
129.6, 127.9, 127.3, 126.7, 69.2, 66.7, 52.3, 42.7, 31.7, 31.5, 31.4, 27.4, 22.3, 13.9.  
 
(2S,2'S)-dimethyl-2,2'-(((4E,4'E)-7,7'-disulfanediylbis(3-hydroxyhept-4-enoyl))bis 
(azanediyl))dihexanoate, Cpd 5’: 
 
 Iodine (0.70 g, 2.8 mmol, 1 equiv.) and sodium acetate (0.45 g, 5.5 mmol, 2 equiv.) were dissolved 
in a 10:1 solution of CH2Cl2/MeOH (15 mL) at 0°C. (2S)-methyl 2-((E)-3-hydroxy-7-
(tritylthio)hept-4-enamido)hexanoate (1.5 g, 2.8 mmol, 1 equiv.) was dissolved in a 10:1 solution 
of CH2Cl2/MeOH (10 mL) and was added dropwise over 20 minutes to the first solution containing 
iodine and sodium acetate. This solution was then allowed to stir for 2 hr.  The reaction was 
quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then brine (15 mL) was added and the phases were separated.  The aqueous layer 
was extracted with dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 mL).  The 
organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was 
purified with column chromatography on silica gel (ethyl acetate, 100%) in presence of 
triethylamine (TEA) and 1.2 g product was obtained with 75 % yield of Cpd 5’.   1H NMR (CDCl3, 
500 MHz): δ (ppm) 6.67 (d, J = 10.0 Hz, 1H), 5.79-5.73 (m, 1H), 5.60 (dd, J = 15.0, 5.0 Hz, 1H), 
4.49 (q, J = 5.0 Hz, 1H), 4.51 (s, 1H), 3.90 (brs, 1H), 3.75 (s, 3H), 2.74 (t, J = 7.5 Hz, 2H), 2.51-





13C NMR (CDCl3, 125 MHz): δ (ppm) 173.3, 171.8, 132.9, 129.3, 69.2, 52.4, 52.2, 42.9, 38.2, 
31.8, 31.7, 27.5, 22.2, 13.8. HRMS (ESI+): Calculated (m/z) for C28H51N2O8S2 (M+H)
+ : 
605.2925, Found 605.2914. 
 
(2S,2'S)-2,2'-(((4E,4'E)-7,7'-disulfanediylbis(3-hydroxyhept-4-enoyl))bis(azanediyl)) 
dihexanoic acid, Cpd 5: 
 
 Iodine (0.24 g, 1.8 mmol, 1 equiv.) and sodium acetate (0.23g, 3.8 mmol, 2 equiv.) were dissolved 
in a 10:1 solution of CH2Cl2/MeOH (15 mL) at 0°C. (2S)-2-((E)-3-hydroxy-7-(tritylthio)hept-4-
enamido)hexanoic acid (1.0 g, 1.8 mmol, 1 equiv.) was dissolved in a 10:1 solution of 
CH2Cl2/MeOH (10 mL) and was added dropwise over 20 minutes to the first solution containing 
iodine and sodium acetate. This solution was then allowed to stir for 2 hr.  The reaction was 
quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then brine (15 mL) was added and the phases were separated.  The aqueous layer 
was extracted with dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 mL).  The 
organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The crude reaction 
mixture was first purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-
580), 0-20min 20-100% ACN/H2O 20ml/min and the detection wave length was set at 210 nm. 
The peak was collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) with 





column under the flow rate of 8ml/min. The wavelength was set at 200 nm to detect the compound 
and 0.55 g of the pure compound was collected at 16-20 min. (55 % yield). The residue was 
purified with column chromatography on silica gel (dichloromethane/methanol, 20:1) with 84% 
yield of Cpd 5.  1H NMR (CD3OD, 500 MHz): δ (ppm) 5.80-5.71 (m, 1H), 5.62 (dd, J = 15.0, 
5.0 Hz, 1H), 4.45 (q, J = 7.5 Hz, 1H), 4.27 (q, J = 3.0 Hz, 1H), 3.76 (t, J = 7.5 Hz, 2H), 2.45 (t, J 
= 7.5 Hz, 4H), 1.85 (t, J = 7.5 Hz, 1H), 1.68 (q, J = 6.0 Hz, 1H), 1.36 (s, 4H), 0.93 (t, J = 3.0 Hz, 
3H); 13C NMR (CD3OD, 125 MHz): δ (ppm) 177.9, 171.4, 133.6, 128.5, 69.0, 54.9, 43.6, 37.7, 
32.4, 31.6, 27.6, 22.3, 13.0. HRMS (ESI+): Calculated (m/z) for C26H44N2O8S2 (M+H)
+ : 




(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (200 mg, 0.48 mmol, 1 equiv.) and aniline (45 L, 
0.48 mmol, 1.0 equiv.) were dissolved in anhydrous dichloromethane (10 mL) under nitrogen. The 
reaction was cooled to 0 ºC. Then, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC 
or EDCI)  (82 mg, 53 mmol, 1.2 equiv.) and 4-dimethylaminopyridinewas (DMAP) (86 mg, 0.12 
mmol,  0.25 equiv. were added to the solution of carboxylic acid and aniline. The reaction was 
allowed to warm to 25ºC and stirred for 12 hr. It was then quenched with a saturated NaHCO3 (10 
mL), extracted with dichloromethane (3 x 15 mL), washed with brine, dried over Na2SO4, and then 





(hexane/ethylacetate, 3:2) and obtained 189 mg of pure product 13 with 80% yield. 1H NMR 
(CDCl3, 500 MHz): δ (ppm) 7.96 (brs, 1H), 7.50 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 9.0 Hz, 6H), 
7.35-7.20 (m, 11H), 7.14 (d, J = 9.0 Hz, 1H), 5.66-5.57 (m, 1H), 6.02 (dd, J = 15.0, 6.0 Hz, 1H), 
4.52 (s, 1H), 3.15 (s, 1H), 2.53 (t, J = 4.5 Hz, 2H), , 2.24 (t, J = 6.0 Hz, 2H), 2.11 (t, J = 6.0 Hz, 
2H); 13C NMR (CDCl3, 125 MHz): δ (ppm) 169.9, 144.9, 137.6, 132.2, 130.5, 129.6, 129.0, 
127.9, 126.7, 124.5, 120.1, 69.3, 66.7, 43.9, 31.4, 31.3. HRMS (ESI+): Calculated (m/z) for 
C32H31N2O2S (M+H)




Iodine (26 mg, 0.20 mmol, 1.0 equiv.) and sodium acetate (33 mg, 0.40 mmol, 2.0 equiv.) were 
dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) at 0°C. (E)-3-hydroxy-N-phenyl-7-
(tritylthio)hept-4-enamide (100 mg, 0.20 mmol, 1.0 equiv.) was dissolved in a 10:1 solution of 
CH2Cl2/MeOH (5 mL) and was added dropwise over 20 minutes to the first solution containing 
iodine and sodium acetate. This solution was then allowed to stir for 2 hr. The reaction was 
quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then, brine (5 mL) was added and the phases were separated.  The aqueous layer 
was extracted with dichloromethane (3 x 5 mL) and then with ethyl acetate (3 x 5 mL).  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified 
with column chromatography on silica gel (dichloromethane/methanol, 50:1) and obtained 65 mg 





Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 5.81-5.71 (m, 1H), 5.64 (dd, J = 15.0, 
6.0 Hz, 1H), 4.56 (q, J = 6.0 Hz, 1H), 2.68 (t, J = 7.5 Hz, 2H), 2.56 (t, J = 7.5 Hz, 2H), 2.41 (q, J 
= 6.0 Hz, 2H); 13C NMR (CD3OD, 75 MHz): δ (ppm) 170.4, 138.3, 133.4, 128.9, 128.4, 123.8, 
119.9, 69.2, 44.5, 37.7, 31.5. HRMS (ESI+): Calculated (m/z) for C26H32N2O4S2 (M-H)
- : 




(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (500 mg, 1.2 mmol, 1.0 equiv.) and tertiary butyl 
amine (125 m, 1.2 mmol, 1.0 equiv.) were dissolved in anhydrous dichloromethane (15 mL) 
under nitrogen. The reaction mixture was cooled to 0 ºC and then benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (746 mg, 1.4 mmol, 1.2 equiv.) was 
added. The solution stirred for 20 min and then DIPEA (832 L, 1.19 mmol, 4 equiv.) was added. 
The reaction was allowed to warm to 25ºC and stirred for 12 hr. It was then quenched with a 
saturated NH4Cl, extracted with dichloromethane (3 x 5 mL), washed with brine, dried over Na2-
SO4, and then concentrated in vacuo. The residue was purified with column chromatography on 
silica gel (hexane/ethylacetate, 1:1) and obtained 407 mg white solid with 72 % yield of 14. 1H 
NMR (CDCl3, 500 MHz): δ (ppm) 7.43 (d, J = 10.0 Hz, 6H), 7.30 (t, J = 7.5 Hz, 6H), 7.23 (t, J = 
7.5 Hz, 3H), 5.66 (brs, 1H), 5.60-5.54 (m, 1H), 5.42 (dd, J = 15.0, 5.0 Hz, 1H), 4.40 (t, J = 7.5 Hz, 
1H), 3.15, 3.92 (s, 1H), 2.31-2.21 (m, 4H), 2.12-2.07 (m, 2H), 1.35 (s, 9H); 13C NMR (CDCl3, 





31.4, 28.8. HRMS (ESI+): Calculated (m/z) for C30H35NO2S (M+Na)
+ : 496.2281, Found 
496.2390. 
 
(4E,4'E)-7,7'-disulfanediylbis(N-(tert-butyl)-3-hydroxyhept-4-enamide), Cpd 8: 
 
Iodine (107 mg, 0.85 mmol, 1.0 equiv.) and sodium acetate (69 mg, 1.7 mmol, 2.0 equiv.) were 
dissolved in a 10:1 solution of CH2Cl2/MeOH (15 mL) at 0°C. (E)-N-(tert-butyl)-3-hydroxy-7-
(tritylthio)hept-4-enamide (400 mg, 0.85 mmol, 1.0 equiv.) was dissolved in a 10:1 solution of 
CH2Cl2/MeOH (5 mL) and was added dropwise over 20 minutes to the first solution containing 
iodine and sodium acetate. This solution was then allowed to stir for 2 hr. The reaction was 
quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then, brine (5 mL) was added and the phases were separated.  The aqueous layer 
was extracted with dichloromethane (3 x 10 mL) and then with ethyl acetate (3 x 10 mL). The 
organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was 
purified with column chromatography on silica gel (dichloromethane/methanol, 20:1) and 
obtained 264 mg white solid with 68 % yield. 1H NMR (CDCl3, 500 MHz): δ (ppm) 5.93 (s, 1H), 
5.75-5.70 (m, 1H), 5.56 (dd, J = 15.0, 5.0 Hz, 1H), 4.45 (s, 1H), 4.22 (s, 1H), 2.74 (t, J = 7.5 Hz, 
2H), 2.68 (q, J = 10.0 Hz, 2H), 2.33-2.25 (m, 2H), 1.35 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ 
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PART III: ACID CATALYZED REACTIONS OF AROMATIC KETONES 


















3-Hydroxyacrylates and their related 3-oxo-esters are useful precursor to synthesize important 
biologically active compounds1-5, drugs compounds6-8, natural products9,10, quaternary carbon 
center containing compounds11-14, and common monomer in polymer15-17 industry because of their 
multifunctional groups reactivity. In organic syntheses, these monomers can also be utilized in 
Michael additions with enolates, amines, and thiols and enantioselective Michael and Mannich 
type reaction with β-keto esters.18-22 Due to the multifunctionality, presence of a prochiral center, 
and preferable substrate scope; 3-hydroxyacrylates have tremendous potential for further 
downstream synthesis of important biologically active compounds.23, 24 Therefore, increasing 
efforts have been devoted to the development of efficient protocols for the synthesis of this 
valuable scaffold by using commercially available starting materials in shorter steps.25,26  
3.1.2. Lewis Acid Catalyzed Reaction: 
Roskamp and his co-worker reacted carbonyl compounds and ethyl diazoacetate (EDA) in 
presence of commercial Lewis acids such as BF3, ZnCl2, ZnBr2, AlCl3, SnCl2, GeCl2, and SnCl4, 
and they reported β-keto esters only.27 In 1998, our group reported an unprecedented formation of 
3-hydroxyacrylates from the reactions of aromatic aldehydes with EDA in the presence of iron 
Lewis acid [ɳ5-(C5H5)Fe
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In the presence of 10 mol% of iron Lewis acid, benzaldehyde was found to consume all the EDA 
to provide 58% of 3-hydroxyacrylate 2a and 25% of 3-oxo ester 3a at room temperature. The 










It was found that the yields of enol esters increased at lower temperatures than room temperature. 
For example, at 0 °C, the yield of the reaction of EDA and benzaldehyde increased to 70% yield 
of 2a and 19% of 3a. Surprisingly, when the reaction was run at lower temperature such as at -78 
°C, the yield of 3-hydroxyacrylates remained the same. When EDA and aldehyde were treated 
without catalyst under the same reaction conditions, neither of the products was formed, and only 
starting materials were isolated from the reaction mixture. The effects of substituents on 
benzaldehyde upon formation of enol esters vs keto esters was determined by the reactions of other 
aromatic aldehydes were investigated. It was found that the yields of enol esters were observed to 
be dependent on the nature of the substituent on benzaldehyde. With electron- rich aldehydes, the 
only product isolated was 3-hydroxyacrylate; no formation of 3-oxo-ester was observed. However, 
in the presence of electron-withdrawing groups in the aldehyde the yield of 3-hydroxyacrylates 
were low. The reaction mechanism was not been fully investigated at that time.  
Kanemasa et al. also described the similar results to ours by utilizing Lewis acid ZnCl2 in the 
presence of chlorotrimethylsilane as catalyst (Scheme 3.2).29 They also mentioned that the types 
of products depending upon the nature of Lewis acid catalysts employed. Reactions catalyzed by 
Lewis acids SnCl2 and SnCl4 yielded 3-oxo-ester via nucleophilic 1, 2-hydride migration. 
 
Scheme 3.2: Formation of 3-Hydroxyacrylate Using ZnCl2 Lewis Acid 
Kirchner and his coworkers reported iron(II) complexes bearing tridentate PNP (diphosphine–
pyridine pincer ligand) type ligands, [Fe(PNP-Ph)(CH3CN)3](BF4)2, as catalysts for the selective 





reported that the acrylate reaction is strongly dependent on the nature of the counterion, whereas 
with BF4






– [Ar’ = 3,5-(CF3)2C6H3] no reaction took place.
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Scheme 3.3: Formation of 3-Hydroxyacrylate Using Fe-PNP Lewis Acid 
Further work by Pe´rez and co-workers using gold-based catalysts of general formulae 
(NHC)AuCl (NHC = N-heterocyclic carbene ligand) for such transformations (Scheme 3.4).32 -
They discovered the gold [IPrAu(NCMe)]BF4 and used in aldehyde and EDA reaction as a catalyst 
and found that it worked really great for the production of 3-hydroxyacrylates. 
 
Scheme 3.4: Formation of 3-Hydroxyacrylate Using Gold Lewis Acid 
Crowley et al. reported the click chemistry with azide type compounds where they used 
Au(SMe2)Cl by immediately the treating of Ag(I) complex was resulting transmetallation provided 
the neutral 1,2,3-triazolylidene gold(I) chloride complex and used as a catalyst to synthesize 
acrylate. These gold(I) ‘‘click’’ carbene complexes used for the self-assembly of a 






Scheme 3.5: Formation of 3-Hydroxyacrylate Using Ag-Lewis Acid 
 
3.1.3. Brønsted Type Acid Catalyzed Reaction 
It was found that formation of 3-hydroxyacrlates or related 3-oxo-esters were in presence of 
different types of Lewis acids catalysts, all the catalysts investigated gave a mixture of 3-
hydroxyacrylate and 3-oxo-ester in different ratios. Some catalysts gave good overall yields in 3-
hydroxyacrylates and others gave 3-oxo-esters in high yields. The most interesting results with 
respect to yield and ratio of products were those reactions catalyzed by SnCl2, HBF4.OEt2, and 
[η5-(C5H5)Fe(CO)2(THF)]BF4. For example, the main product observed from SnCl2 and 
SnCl2.2H2O is the 3-oxo-ester. In comparison, [η
5-(C5H5)Fe(CO)2(THF)]BF4 gave mainly 3-
hydroxyacrylate.4 Surprisingly, it was observed that HBF4.OEt2 also catalyzes the reaction 
between aromatic aldehydes and EDA to provide 3-hydroxyacrylates in good yields versus the 
corresponding 3-oxo-esters. The idea of using the HBF4.OEt2 acid as a catalyst came from the fact 
that HBF4.OEt2 is used in the synthesis of [η
5-(C5H5)Fe(CO)2(THF)]BF4.
4 Hossain and co-workers 
thought that acid impurities from HBF4.OEt2 could be a possible source of catalytic activity. To 
establish that [η5-(C5H5)Fe(CO)2(THF)]BF4, and not HBF4.OEt2 impurities, was truly the catalyst 
in the reaction of aromatic aldehydes with EDA, the reaction was performed in the presence of 
proton sponge, 1,8-bis(dimethylamino)naphthalene. The activity of [η5-(C5H5)Fe(CO)2(THF)]BF4 
was not inhibited by the addition of proton sponge. Proton sponge experiment showed that with 
HBF4.OEt2, the reaction was almost completely inhibited by the addition of proton sponge and 





experiment, in 1998, our group also explored the reactions with the Brønsted type, specifically 
HBF4.OEt2, to produce 3-hydroxyacrylates and 3-oxo-esters from the same starting materials 
(Scheme 3.6).34 
 
Scheme 3.6: Synthesis of 3-Hydroxyacrylates by Hossain et al.in 2004 
 
It had been reported that substituents on the aromatic aldehyde play an important role in product 
distribution when reactions are catalyzed by iron Lewis acid, [η5-(C5H5)Fe(CO)2(THF)]BF4 
catalyst. Electron-donating groups favor the formation of 3-hydroxyacrylates, whereas electron-
withdrawing groups favor the 3-oxo-ester. To prove the statement, several reactions were 
performed by using iron Lewis acid as well as Brønsted type acid, and all reactions were carried 
out at room temperature under the same conditions for comparison. Analysis of aromatic ketones 
such as acetophenone and trifluoroacetophenone showed that only acetophenone reacted with 
HBF4.OEt2, while no reaction was observed in the presence of iron Lewis acid, whereas 
trifluoroacetophenone was unreactive regardless of the catalyst used. From the inspiration of 
Brønsted type acid, HBF4.OEt2, it was investigated with other Brønsted type acids with varying 





- > Cl- and CH3COO
-. Those Brønsted acids with nonnucleophilic anions gave the best 
results, for example, sulfuric acid and HBF4.OEt2. In each case where a metal-halogen type catalyst 
(SnCl2, AlCl3) was utilized in the reaction, significantly produced more 3-oxo-esters than 3-
hydroxyacrylate. Kanemasa and coworkers suggested that chelation transition state orients the 





this transition state reduces the steric interactions and facilitates 3-oxo-ester formation. The 
catalysts, other than those of the metal-halogen type, Brønsted type acid, HBF4.OEt2, bind to the 
aldehyde first and then the nucleophilic methine carbanion of EDA can attack either the re- or si-
face of the aldehyde. In this situation, six Newman projections have been drawn and explained by 
Hossain and coworkers34 (Figure 3.2).  
 
Figure 3.2: Stable and Unstable Rotamers of Benzaldehyde and EDA Reaction 
 
Among all rotamers (Figure 3.2), ‘A’ and ‘F’ two rotamers have leaving group and aryl migrating 
are antiperiplanar but rotamer ‘A’ has less energy than ‘F’ because of less bulky group interaction, 
so product of 3-hydroxyacrylates were formed more from the rotamer ‘A’. For 3-oxoesters, in 
rotamer ‘C’ and ‘D’, leaving group and hydride migrating group were antiperiplanar, but this 
rotamer ‘C’ has little higher energy by the comparison with rotamer ‘D’, for this reason oxo-ester 
yielded from rotamer ‘D’. Actually, 3-hydroacrylates were more than 3-oxoesters because between 
rotamers ‘A’ and ‘D’, transition state of aryl migration from rotamer ‘A’ (Figure 3.2 “G’) makes a 





3.1.4. Base Catalysed Reaction  
Wang et al. reported DBU-catalyzed condensation of ethyl diazoacetate (EDA) with aldehydes in 
pure water afforded corresponding β-hydroxy α-diazo carbonyl compounds, the β-hydroxy group 
was further converted into β-siloxy group and gave 1,2-aryl shift products predominantly by 




























Scheme 3.7: Synthesis of 3-Hydroxyacrylates by Wang et al. 
3.2. Application of 3-hydroxyacrylates 
In 1998, Schmittel and his coworker reported a short and efficient preparation of 3,8-dialkylated 
or 3,8-diarylated 1,10-phenanthrolines-4,7-diones (Scheme 3.8). They used hydroxy acrylate as a 
one of the important starting materials. 1,10-Phenanthrolines have been used as important ligands 
for a vast amount of metal complexes.36 
 





Naproxen, 2-(6-methoxy-2-naphthyl)propenoic acid was synthesized in good yield from 
commercially available 6-methoxy-2-naphthaldehyde in three steps. The synthesis includes an 
unprecedented one-step reduction of acrylic acid ethyl ester to propenoic acid ethyl ester in high 
yield (Scheme 3.9).7 α-arylpropanoic acids is of great commercial interest as they are widely used 


















Scheme 3.9: Synthesis of Naproxen from 3-Hydroxyacrylates 
Hossain et al. reported the first kinetic resolution of tropic acid ethyl ester (TAEE) with lipase PS 
and vinyl acetate as an acylating agent (Scheme 11).1,2 The resulting (S)-(_)-3-acetoxy tropic acid 
ethyl ester and (R)-(+)-tropic acid ethyl ester is produced in high yields and in excellent ee (87–
94%). The method has been extended to resolve a variety of tropic acid ester derivatives. In 
addition, an improved method for the preparation of racemic mixtures of tropic acid ethyl ester 
and its derivatives from 3-hydroxy-2-phenylacrylic acid ethyl ester using NaBH4 in methanol is 
reported. This procedure is better than the previous ones because it is cleaner, safer and can be 
worked up easily. An improved method of deacylating the chiral 3-acetoxy tropic acid ethyl ester 
without any loss of stereochemical integrity using HCl/CH3OH is also reported. (S)-(-)-Tropic acid 
is an important building block for bio-logically active tropane alkaloids, such as hyoscyamine and 
scopolamine. The dynamic kinetic resolution of racemic mixtures of tropic acid ethyl ester under 
substrate racemizing conditions was studied using lipase PS with a ruthenium catalyst by Hossain 







Scheme 3.10: Kinetic Resolution of Tropic Acid Ethyl Ester (TAEE) 
Hossain group developed a convenient one-pot procedure for the synthesis of 3-
ethoxycarbonylbenzofurans from commercially available salicylaldehydes and ethyl diazoacetate 
(Scheme 3.11).24 The method is high-yielding, efficient, simple and selective. Benzofuran is a very 
pivotal precursor for the synthesis of many pharmaceutical and biologically active compounds. 
 
Scheme 3.11: Synthesis of 3-Ethoxycarbonylindole 
A convenient one-step synthesis of 5-aryl uracils has been developed. The procedure involves 
heating ethyl 3-hydroxy-2-arylpropenate with urea followed by base-catalyzed cyclization. The 
method is simple and high yielding (Scheme 3.12).6 
 





A large number of biologically active compounds consist of an indole scaffolding. Because of this, 
chemists are continually searching for more efficient means through which to successfully 
synthesize the required alkaloids (Scheme 3.13).23 
 
Scheme 3.13: Synthesis of Gramine from 3-Hydroxyacrylate 
The formation of α-aryl quaternary carbon centers, pre-sent in a growing number of biologically 
active natural products and pharmaceutical agents, poses a unique challenge due to the steric 
congestion encountered during the C–C bond formation process. Generally, a quaternary aryl 
carbon center is formed using strongly basic lithium arenes. In 2010, Hossain at el. described a 
Claisen rearrangement process for generating α-aryl quaternary car-bon centers from 3-allyloxy-
2-arylacrylates, made from arylhydroxyacrylates (Scheme 3.14). Although Claisen 



















Scheme 3.14: Synthesis of α-Aryl Quaternary Carbon Centers 
Later, Hossain and coworkers described a set of acyclic all-carbon α-aryl quaternary aldehydes by 
intermolecular palladium-catalyzed asymmetric allylic alkylation (Pd-AAA) in 2014 (Scheme 
3.15). Hydroxyacrylates were used as unprecedented nucleophilic counterparts instead of widely 





(R,R)-L3 was found to be optimal in this Pd-AAA reaction and pro-vided good to excellent yields 
(75–99%) and enantioselectivities (75–94%) with a range of analogs.12 
 
Scheme 3.15: Synthesis of Asymmetric α-Aryl Quaternary Carbon Centers by AAA Reaction 
In 2015, Hossain at el. Reported a stereoselective synthesis of carbonates derived from 3-hydroxy- 
2-aryl acrylates that can form the Z- or E-stereoisomer in very high Z/E ratios (50:1 and 1:99, 
respectively) (Scheme 3.16). The stereochemical outcome depends on the choice of base, addition 
of TMEDA and reaction temperature. The Z- and E-stereoisomers have different reactivities 
towards the decarboxylative asymmetric allylic alkylation (DAAA) reaction, with the E-
stereoisomer displaying both greater reactivity and enantiodifferentiation with chiral ligands. The 
DAAA of E-stereoisomer analogues takes place in excellent yields ranging from 96–99% and 
enantioselectivities ranging from 42–78% ee.13 
 






Later, in 2018, Hossain and coworkers reported the first palladium(0)-catalyzed asymmetric allylic 
alkylation (AAA) of allyl enol ether via p-allylpalladium intermediate using Trost chiral 
diphosphine (Scheme 3.17).17 This unprecedented reaction produced very rare a-aryl quaternary 
aldehydes with multi-functional groups. The main novelty in the chemistry demonstrates that enol 
ethers can be used as precursors for p-allylpalladium intermediates, an observation that is certainly 
rare and to the best of our knowledge, perhaps without prior precedent. Chiral ligand (R, R)-L3 
was found to be optimal in this Pd-AAA reaction and provided good to excellent yield (80–95%) 

























Scheme 3.17: Synthesis of Asymmetric Quaternary Carbon Centers from O-Allylated Enol-Ether 
 
Hossain and coworkers developed a concise method of synthesizing racemic arylpropanoic acids, 
which have been widely used as nonsteroidal anti-inflammatory drugs (NSAIDs) (Scheme 3.18). 
The synthesis involves only four steps from commercially available benzaldehyde. The synthesis 
incorporates an unprecedented reduction reaction, conversion of 3-hydroxy-2-arylpropenoic acid 
ethyl ester to 2-arylpropenoic acid ethyl ester by BH3 · THF. The reduction reaction has been 






Scheme 3.18: Synthesis of Arylpropanoic Acids 
Telvekar and coworkers synthesized N’-benzylidene ben-zofuran-3-carbohydrazides from 3-
ethoxycarbonyl benzo-furans (Scheme 3.19).20 All these compounds were found to be active 

















R1 = H, R2 = H




















Scheme 3.19: Synthesis of N’-Benzylidene Benzofuran-3-Carbohydrazide 
Eccles and coworkers synthesized several leukotriene A4 hydrolase (LTA4H) inhibitors from 3-
ethoxycarbonyl benzofuran (Scheme 3.20).21 LTA4H inhibitors are used in inflammatory diseases, 









































NR1R2 = Piperidine, morpholine, 




Scheme 3.20: Synthesis of Leukotriene A4 Hydrolase (LTA4H) Inhibitor 
Morrow et al. synthesized pterocarpenes and coumestans type heterocycles by the Mitsunobu 
coupling of 3-hydroxymethylbenzofurans with ortho-iodophenols (Scheme 3.21). Pterocarpans 
group have been shown to exhibit broad spectrum activity against Gram-positive bacteria and 
vancomycin-resistant strains of enterococci. Coumestans such as coumestrol and flemmichapparin 





































Pterocarpenes Coumestans  






Tolstikov et al. reported several regioselective Diels–Alder reactions of Danishefsky’s diene with 
3-ethoxycarbonyl benzofurans (Scheme 3.22).40 These reactions provided effective method for the 
construction of heterocyclic skeleton of hexahydrodibenzofuran-7-one and 
tetrahydrodibenzofuran-7-one. These tricyclic fragments are the structural motifs of many 
pharmacologically vital substances, such as plant alkaloids morphine, galanthamine, lycoramine, 


















1. H4NF, MeOH, -15 °C
2. TsOH, MeOH, rt
3. CF3COOH, CH2Cl2, rt


















Scheme 3.22: Diels–Alder Reactions of 3-Ethoxycarbonyl Benzofuran 
 
Elofssan and coworkers constructed a library based on 3-carboxy 2-aryl benzofuran scaffold from 
the 3-ethoxycarbonyl benzofuran (Scheme 3.23).41 These two scaffolds are core components in 
many biologically active natural and synthetic compounds of which many display a wide range of 
























































Scheme 3.23: Synthesis of 2-Arylbenzofuran-3-Carboxamide Derivatives 
Zhao et al. reported a total synthesis of paeoveitol, the norditerpene natural product which has 
antidepressant ability, from 3-ethoxycarbonyl benzofuran (Scheme 3.24).42 Our published 
procedure was employed to synthesize 3-ethoxycarbonyl benzofuran, which was reduced to 
Paeoveitol D. Paeoveitol was synthesize by an unusual intermolecular ortho-quinone methide 

































PaeoveitolPaeoveitol D  





Chen and coworkers reported the first catalytic asymmetric total synthesis of (+)-paeoveitol and (-
)-paeoveitol from 3-ethoxycarbonyl benzofuran via a biomimetic hetero-Diels-Alder reaction in 























































Scheme 3.25: Asymmetric Synthesis of (+)-Paeoveitol and (-)-Paeoveitol 
Bongen et al. reported an efficient asymmetric synthesis of 7-benzoyl-2,3-dihydro-1-benzofuran-
3-carboxylic acid, BRL-37959 (Scheme 3.26).44 3-Ethoxycarbonyl benzofuran was reduced by 
magnesium turnings to form 2,3-dihydrobenzofuran-3-carboxylic acid ethyl ester and resolved by 
dynamic kinetic resolution. Friedel-Crafts acylation of the enantiopure product followed by acidic 







CAL-B, 36 °C 
KPi buffer
 




































Recently, in 2018, our group reported the synthesis of 7-benzoyl-2,3-dihydro-1-benzofuran-3-
carboxylic acid, BRL-37959 and its analogs from 3-ethoxycarbonyl benzofuran (Scheme 3.27).45 
To synthesize BRL-37959, incorporation of benzoyl group at the C-6 position of benzofuran ring 
by the Friedel-Crafts acylation reaction was main challenge. Our recent method demonstrates that 
bismuth (III) trifluoromethanesulfonate can be used as a catalyst for the Friedel-Crafts acylation 
reaction with good yield. It is reported in the synthetic procedure, 3-ethoxycarbonyl benzofuran 
was synthesized by our previous established method and reduced by a Mg/MeOH mixture 
followed by using as a catalyst to produce 7-benzoyl-2,3-dihydro-1-benzofuran-3-carboxylate. 
Basic hydrolysis of this carboxylate was converted to carboxylic acid and formed the desired 
product of BRL-37959. This efficient method allowed us for the production in high yields as well 





 HBF4.Et2O, CH2Cl2, rt































Scheme 3.27: Synthesis of BRL-37959 and Its Analogs 







3.3. Present Synthesis of 3-Hydroxyacrylates  
In our previous work, we studied the reaction of acetophenone with EDA, which yielded 
exclusively 3-hydroxyacrylate product (Scheme 3.28).13 To expand the scope of this reaction, 
phenyl-alkyl ketones were employed as substrates in this transformation, and the results are 
summarized in Table 3.1. 
 
Scheme 3.28: Synthesis of 3-Hydroxyacrylates from Ketones 
From the perceptive nature of phenyl and methyl groups of acetophenone, the reactions were 
extended to other aromatic ketones beyond acetophenone to examine the substrate scope for 
aromatic ketones with different alkyl groups. The results of these reactions are summarized in 
Table 3.1. When propiophenone was employed as a substrate for this transformation, the desired 
phenyl group migrated product, 3-hydroxyacrylate 3b along with ethyl group migrated product, 3-
oxo-ester 3b’ was obtained in 62% yield. The oxo-ester 3b’ was isolated, and the structure was 
characterized by NMR and confirmed by comparison with the authentic compounds. This 
migratory tendency of different phenyl and alkyl groups from isolated yield of our synthetic 
products in this cate-gory were almost similar, (3-hydroxyacrylates/oxo-esters > 1.2:1) (3b-f). 
However, when the reaction was carried out with octanophenone as a substrate, the corresponding 










where, R = CH3, C2H5, C3H7, C4H9, C5H11, C6H13, and C7H15. 
 
To understand longer chain effects of phenyl-alkyl ketones, we next examined the substrate scope 
for aromatic ketones with different alkyl groups with EDA employed as the reaction partner. The 
results of these reactions are summarized in Table 3.1. From these reactions we found two types 
of products from two different migrations. From general studies on the relative migration aptitude, 
the following order has been found: tertiary alkyl > cyclo-hexyl > secondary alkyl > benzyl > 







3.4. Conclusion and Future Works 
Aldehydes and ethyl diazoacetate produced 3-hydroxy acrylates in presence of Lewis or Brønsted 
acid catalyst. Less reactive aromatic/aliphatic ketones and aldehydes also yielded the 3-hydroxy 
acrylates and 3-oxo-esters. A bunch of 3-hydroxy acrylates and related 3-oxo-esters are 
synthesized from different kinds carbonyl substrates. A large number of biological active 
compounds as well as quaternary carbon center containing compounds could be synthesized by 




















3.5. General Consideration 
All reactions were performed under a dry nitrogen atmosphere using standard Schlenk techniques 
unless otherwise noted.  All reaction vessels were flame dried under vacuum and filled with 
nitrogen prior to use. Reagents and solvents were purchased from Sigma-Aldrich, Milwaukee. All 
1H and 13C NMR spectra were recorded in CDCl3 (internal standard: 7.26 ppm, 
1H; 77.16 ppm, 
13C) at room temperature with a Burker 300 MHz and 500 MHz spectrometers. The chemical shifts 
(δ) are given in parts per million (ppm) and the coupling constants in Hertz (Hz). All new 
compounds were additionally characterized by 1H NMR, 13C NMR and high-resolution mass 
spectrometry (HRMS). HRMS were obtained using electrospray ionization (ESI) technique. For 
column chromatography, silica gel (35-70 microns) was used. Thin layer chromatography (TLC) 
was performed on aluminum backed plates pre-coated (0.25 mm) with Silica Gel 60 F254 with a 
suitable solvent system and was visualized using UV fluorescence and/or iodine chamber. 
 
3.5.1. General Procedure and Experimental 
For each experiment, 1.5-5.0 mmol of the carbonyl compounds was dissolved in 15-25 mL of 
freshly distilled dichloromethane under nitrogen. A Brønsted acid, HBF4∙OEt2 catalyst (0.1-0.2 
equiv) of was added, and the reaction mixture was stirred for 1 hour. Ethyl diazoacetate (EDA) 
(1.2-2.0 equiv) was diluted in 5 mL of freshly distilled dichloromethane and added to the aldehyde 
over a period of 6-7 h. The reaction mixture was allowed to stir for an additional 36 h, and each 
reaction was quenched by adding THF. The reaction mixture was filtered through a silica plug and 
the solvent removed by rotary evaporation. Crude products were isolated by silica column 











Ethyl 3-oxo-2-phenylbutanoate (keto-enol tautomer) as a colorless liquid (3a) 
The title compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3a as a colorless oil with 60% yield. Compound 3a was 
confirmed by comparing to known NMR. 
1H NMR (CDCl3, 300 MHz): δ 13.15 (s, 1H), 7.40-7.29 (m, 8H), 7.19-7.16 (m, 2H), 4.71 (s, 1H), 
4.26-4.16 (m, 4H), 2.21 (s, 3H), 1.87 (s, 3H), 1.30 (t, J = 7.5 Hz, 3H), 1.21 (t, J = 7.5 Hz, 3H). 13C 
NMR (CDCl3, 125 MHz): δ 201.6, 173.9, 172.6, 168.5, 135.3, 132.7, 131.2, 129.3, 128.9, 128.3, 
128.0, 126.9, 104.4, 65.8, 61.6, 60.6, 28.8, 19.9, 14.2, 14.1. HRMS (ESI+): Calculated (m/z) for 
C12H15O3 (M+H)
+ : 207.1016, Found 207.0987. 
Ethyl 3-oxo-2-phenylpentanoate (keto-enol tautomer) as a colorless liquid (3b) 
The title compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3b and 3b’ as a colorless oil with 62% yield.  
1H NMR (CDCl3, 300 MHz): δ 13.23 (s, 1H), 7.37-28 (m, 8H), 7.18 (t, J = 4.5 Hz, 2H), 4.76 (s, 
1H), 4.26-4.14 (m, 4H), 2.53 (q, J = 6.0 Hz, 2H), 2.15 (q, J = 6.0 Hz, 2H), 1.28 (t, J = 7.5 Hz, 3H), 
1.18 (t, J = 7.5 Hz, 3H), 1.12-1.01 (m, 6H). 13C NMR (CDCl3, 75 MHz): δ 204.2, 178.1, 172.8, 
168.7, 135.2, 133.0, 131.2, 129.4, 128.8, 128.1, 128.0, 126.9, 103.6, 64.8, 61.5, 60.5, 34.9, 26.3, 
14.2, 14.0, 11.1, 7.8. HRMS (ESI+): Calculated (m/z) for C13H17O3 (M+H)













Ethyl 2-benzoylbutanoate (β-keto ester) as a colorless liquid (3b’) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3b and 3b’ as a colorless oil with 62% yield. Compound 
5a’ was confirmed by comparing to known NMR. 
1H NMR (CDCl3, 300 MHz): δ 7.98 (d, J = 9.0 Hz, 2H), 7.55 (t, J = 6.0 Hz, 1H), 7.48 (t, J = 6.0 
Hz, 2H), 4.21 (t, J = 6.0 Hz, 1H), 4.12 (q, J = 9.0 Hz, 2H), 2.07-1.98 (m, 2H), 1.14 (t, J = 6.0 Hz, 
3H), 0.98 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 195.2, 169.9, 136.4, 133.4, 128.7, 
128.5, 61.2, 55.8, 22.4, 14.0, 12.1.  
 
Ethyl 3-oxo-2-phenylhexanoate (keto-enol tautomer) as a colorless liquid (3c)  
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3c and 3c’ as a colorless oil with 60% yield.  
1H NMR (CDCl3, 300 MHz): δ 13.20 (s, 1H), 7.40-7.30 (m, 8H), 7.18 (d, J = 5.0 Hz, 2H), 4.74 
(s, 1H), 4.27-4.17 (m, 4H), 2.48 (t, J = 7.5 Hz, 2H), 2.11 (t, J = 8.0 Hz, 2H), 1.63-1.55 (m, 4H), 
1.29 (t, J = 6.0 HZ, 3H), 1.19 (t, J = 6.0 Hz, 3H), 0.89-0.83 (m, 6H). 13C NMR (CDCl3, 75 MHz): 
δ 203.7, 176.9, 172.9, 168.6, 135.2, 132.8, 131.4, 129.5, 128.8, 128.2, 128.0, 126.9, 104.3, 65.0, 
61.6, 60.6, 43.5, 34.7, 20.1, 17.1, 14.2, 14.1, 13.8, 13.4. HRMS (ESI+): Calculated (m/z) for 
C14H19O3 (M+H)












Ethyl 2-benzoylpentanoate (β-keto ester) as a colorless liquid (3c’) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3c and 3c’ as a colorless oil with 60% yield. Compound 
3c’ was confirmed by comparing to known NMR. 
1H NMR (CDCl3, 300 MHz): δ 7.98 (t, J = 4.5 Hz, 2H), 7.55 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 
Hz, 2H), 4.31 (t, J = 7.5 Hz, 1H), 4.15 (q, J = 6.0 Hz, 2H), 2.04-1.95 (m, 2H), 1.43-1.33 (m, 2H), 
1.17 (t, J = 7.5 Hz, 3H), 0.95 (t, J = 7.5 Hz, 3H). 
 
Ethyl 3-oxo-2-phenylheptanoate (keto-enol tautomer) as a colorless liquid (3d) 
 The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3d and 3d’ as a colorless oil with 45% yield.  
1H NMR (CDCl3, 300 MHz): δ 13.20 (s, 0.4H), 8.15 (d, J = 5.0 Hz, 1H), 7.51 (t, J = 5.0 Hz, 1H), 
7.51-7.35 (m, 7H), 7.17 (d, t, J = 5.0 Hz, 1H), 4.73 (s, 1.3H), 4.30-4.16 (m, 4H), 2.49 (t, J = 7.5 
Hz, 2H), 2.12 (t, J = 7.5 Hz, 2H), 1.56-1.53 (m, 4H), 1.30-1.24 (m, 7H), 1.22 (t, J = 4.5 Hz, 3H), 
0.93-0.80 (m, 6H). 13C NMR (CDCl3, 75 MHz): δ 203.6, 176.8, 172.8, 168.5, 135.1, 132.7, 131.3, 
129.4, 128.8, 128.1, 127.9, 126.8, 104.2, 65.0, 61.5, 60.5, 43.4, 34.6, 20.0, 17.0, 14.2, 14.0, 13.7, 
13.4. HRMS (ESI+): Calculated (m/z) for C15H21O3 (M+H)













Ethyl 2-benzoylhexanoate (β-keto ester) as a colorless liquid (3d’) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate = 
100:1) to afford 3e and 3e’ as a colorless oil with 45% yield. Compound 
3e’ was confirmed by comparing to known NMR. 
1H NMR (CDCl3, 300 MHz): δ 8.01 (d, J = 9.0 Hz, 2H), 7.55 (d, J = 6.0 Hz, 1H), 7.48 (t, J = 7.5 
Hz, 2H),  4.30 (t, J = 7.5 Hz, 1H), 4.12 (q, J = 15.9, 9.0 Hz, 2H), 2.03 (q, J = 12.0, 6.0 Hz, 2H), 
1.36-1.28 (m, 4H), 1.19 (t, J = 7.5 Hz, 3H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 
δ 195.3, 170.1, 136.4, 133.4, 128.7, 128.6, 61.3, 54.4, 29.8, 28.7, 22.5, 14.0, 13.8.  
 
 Ethyl 3-oxo-2-phenyloctanoate (keto-enol tautomer) as a colorless liquid (3e) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate 
= 100:1) to afford 3e and 3e’ as a colorless oil with 55% yield.  
1H NMR (CDCl3, 300 MHz): δ 13.26 (s, 1H), 7.41-28 (m, 8H), 7.19 (t, J = 6.0 Hz,2H), 4.77 (s, 
1H), 4.26-4.14 (m, 4H), 2.51 (t, J = 7.5 Hz, 2H), 2.14 (t, J = 7.5 Hz, 2H), 1.63-1.54 (m, 4H), 1.43-
1.32 (m, 14H), 0.89-0.83 (m, 6H). 13C NMR (CDCl3, 75 MHz): δ 203.6, 177.2, 172.8, 168.5, 
135.2, 132.9, 131.3, 129.5, 128.7, 127.9, 126.9, 104.1, 65.0, 61.4, 60.5, 41.5, 32.7, 31.3, 31.1, 26.4, 
23.3, 22.3, 22.3, 22.2, 14.1, 14.0. HRMS (ESI+): Calculated (m/z) for C16H23O3 (M+H)
+ : 












Ethyl 2-benzoylheptanoate (β-keto ester) as a colorless liquid (3e’) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate 
= 100:1) to afford 3e and 3e’ as a colorless oil with 55% yield.  
1H NMR (CDCl3, 300 MHz): δ 8.01 (d, J = 9.0 Hz, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.5 
Hz, 2H),  4.30 (t, J = 7.5 Hz, 1H), 4.16 (q, J = 7.5 Hz, 2H), 2.05-1.98 (m, 2H), 1.39-1.27 (m, 6H), 
1.18 (t, J = 7.5 Hz, 3H). 0.88 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 195.3, 170.1, 
136.4, 133.4, 128.7, 128.7, 128.6, 128.5, 61.3, 54.4, 31.6, 28.9, 27.3, 22.4, 13.9. HRMS (ESI+): 
Calculated (m/z) for C16H23O3 (M+H)
+ : 263.1642; Found 263.1649. 
 
Ethyl 3-oxo-2-phenylnonanoate (keto-enol tautomer) as a colorless liquid (3f) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate 
= 100:1) to afford 3f and 3f’ as a colorless oil with 48% yield.  
1H NMR (CDCl3, 300 MHz): δ 13.20 (s, 1H), 7.39-7.29 (m, 9H), 7.18-7.15 (m, 1H), 4.74 (s, 1H), 
4.26-4.17 (m, 4H), 2.50 (t, J = 7.5 Hz, 3H), 2.12 (t, J = 7.5 Hz, 2H), 1.58-1.54 (m, 4H), 1.31-1.18 
(m, 18H), 0.89-0.84 (m, 6H). 13C NMR (CDCl3, 75 MHz): δ 203.7, 177.2, 172.9, 168.6, 135.2, 
132.8, 131.3, 129.6, 129.4, 129.0, 128.8, 128.1, 128.0, 126.9, 104.1, 65.0, 61.5, 60.5, 41.9, 32.7, 
31.5, 28.8, 28.5, 26.6, 23.6, 22.4, 14.2, 14.1, 14.0. HRMS (ESI+): Calculated (m/z) for C17H25O3 












Ethyl 2-benzoyloctanoate (β-keto ester) as a colorless liquid (3f’) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate 
= 100:1) to afford 3f and 3f’ as a colorless oil with 48% yield.  
1H NMR (CDCl3, 300 MHz): δ 8.01 (d, J = 9.0 Hz, 2H), 7.60 (t, J = 6.0 Hz, 1H), 7.49 (t, J = 7.5 
Hz, 2H), 4.30 (t, J = 7.5 Hz, 1H), 4.16 (q, J = 7.5 Hz, 2H), 2.03 (d, J = 3.0 Hz, 2H), 1.36-1.27 (m, 
8H), 1.19 (t, J = 6.0 Hz, 3H), 0.88 (t, J = 6.0 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 195.3, 170.1, 
136.4, 133.4, 128.7, 128.6, 61.3, 54.4, 31.5, 29.7, 29.1, 29.0, 27.6, 22.5, 14.0. HRMS (ESI+): 
Calculated (m/z) for C17H25O3 (M+H)
+ : 277.1798; Found 277.1860. 
 
Ethyl 3-oxo-2-phenyldecanoate (keto-enol tautomer) as a colorless (3g) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate 
= 100:1) to afford 3g and 3g’ as a colorless oil with 37% yield.  
1H NMR (CDCl3, 300 MHz): δ 13.18 (s, 1H), 7.37-28 (m, 8H), 7.16 (d, J = 6.0 Hz, 2H), 4.73 (s, 
1H), 4.27-4.15 (m, 4H), 2.49 (t, J = 7.5 Hz, 2H), 2.11 (t, J = 7.5 Hz, 2H), 1.62-1.55 (m, 4H), 1.31-
1.17 (m, 22H), 0.89-0.85 (m, 6H). 13C NMR (CDCl3, 75 MHz): δ 203.8, 177.2, 172.9, 168.6, 
135.2, 132.8, 131.3, 129.4, 128.8, 128.1, 127.9, 126.9, 104.1, 65.0, 61.5, 60.6, 41.6, 32.7, 31.6, 
29.1, 28.9, 28.8, 26.7, 23.6, 22.6, 22.6, 14.2. HRMS (ESI+): Calculated (m/z) for C18H27O3 









Ethyl 2-benzoylnonanoate (β-keto ester) as a colorless liquid (3g’) 
The compound was prepared according to the general procedure and 
purified by silica gel column chromatography (hexane/ethyl acetate 
= 100:1) to afford 3g and 3g’ as a colorless oil with 37% yield.  
1H NMR (CDCl3, 300 MHz): δ 8.01 (d, J = 9.0 Hz, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.49 (t, J = 7.5 
Hz, 2H),  4.29 (t, J = 7.5 Hz, 1H), 4.15 (q, J = 7.5 Hz, 2H), 2.03-1.98 (m, 2H), 1.34-1.27 (m, 10H), 
1.18 (t, J = 7.5 Hz, 3H). 0.88 (t, J = 6.0 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 195.3, 170.1, 
136.4, 133.4, 128.7, 128.5, 61.3, 54.4, 31.7, 29.4, 29.0, 29.0, 27.6, 22.6, 14.0, 14.0. HRMS (ESI+): 
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PART I: A CONCISE ASYMMETRIC SYNTHESIS OF MICROTUBULE 

































































































































































































































































































































































































Crystal Structure Data of Compound 7 
 
CCDC 922382 DOI: 10.5517/ccdc.csd.cczyt8z 
Blocks grown using slow diffusion method: Ethyl Acetate/Hexane 
Analyzed by X-ray diffraction at UCSD with Arnold L. Rheingold 
Unit Cell Dimensions:  a=8.5784(2) Å; b=12.9668(3) Å; c=13.5267(3) Å 
                                      α=109.266(2)°; β=103.084(2)°; γ=107.596(2)° 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PART III: ACID CATALYZED REACTIONS OF AROMATIC KETONES 
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